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1 Introduction and objectives 
1.1 Introduction 
Scalp psoriasis is a frequently occurring pathological dermal condition affecting 
approximately 2% of the Western population (van de Kerkhof and Franssen, 
2001). It affects at least 80% of patients suffering of psoriasis (Wozel, 2008). 
Plaque type psoriasis (Psoriasis vulgaris) is the most common form of it. Due to 
psychological and social distress, the quality of life can be seriously reduced by 
this disease (van de Kerkhof and Franssen, 2001; Szepietowski et al., 2009). 
Despite of numerous available treatment options of scalp psoriasis, therapeutic 
experience of patients and physicians is reported to be disappointing. This fact 
was recently confirmed by a survey of 17.990 patients with scalp psoriasis in 
7 European countries (Wozel, 2008). 
Seborrheic dermatitis (SD) is a chronic, recurrent skin condition that affects 
3% to 5% of the population (High et al., 2006). It mostly affects the scalp 
(dandruff), but can also affect skin on other parts of the body. 
The eventuality of scalp skin involvement and the necessity of topical 
corticosteroid application to the scalp skin is a common feature of these two 
pathological conditions.  
Drug delivery to the scalp skin is a challenge for galenical formulation 
development, as the patient’s acceptance of the vehicle should be assured in 
terms of cosmetical satisfactoriness and application comfort. Nevertheless, 
cosmetical unacceptability and application discomfort are often negative 
features of the vehicles on the market leading to therapy refusal. The vehicles 
used to deliver the topical therapeutics have been shown to have a considerable 
impact on patients´ compliance (Chan et al., 2009). Poor compliance is reported 
to be an important factor for reduced clinical efficacy (Feldman et al., 2000).  
Ointments, creams, lotions, gels and solutions represent traditional topical 
delivery vehicles used in the treatment of scalp psoriasis and other topical 
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pathological conditions of the scalp requiring topical delivery of corticosteroids. 
However, all these conventional vehicles have drawbacks when being applied 
on hairy body regions due to viscosity limitations, finally affecting cosmetic hair 
condition (e.g. oily hair, brittle hair, dryness of scalp skin, unpleasant smell) 
(Stein, 2005; Wozel, 2008). These drawbacks are often dictated by the 
excipients. Ointments comprise high viscous, non-volatile vehicles which can be 
unpleasant to apply and often difficult to remove from scalp and clothing. 
Creams, ointments and gels can leave residues after application and stain 
clothing. Solutions often run off from the site of application because of their low 
viscosity. Moreover, patients with affected hairy body regions complain the 
conventional topical therapy to be time-consuming to apply and remove as well 
as often cosmetically unacceptable (Feldman and Housman, 2003). 
Another realistic problem of topical scalp treatment is the availability of the 
active compound on the skin surface. If a preparation is evenly distributed to the 
hair and the scalp, the skin exposure is between 20 and 100 times lower than that 
of the hair surface. Thus, any patient will carefully make an effort to avoid hair 
exposure with a preparation, leading to a decreased active compound exposure 
to the scalp skin. Moreover, a high sebum content of the scalp can lead to a 
decrease in the availability of lipophilic components for penetration (Wozel, 
2008).   
Shampoos represent another vehicle for the treatment of pathological scalp 
conditions. Ketoconazole shampoos are used for the treatment of seborrheic 
dermatitis for example. Nevertheless, the disadvantage of these vehicles is short 
application time only during the washing process. 
Foams for dermal application represent new drug delivery vehicles to deliver 
drugs to the scalp. Theses vehicles have certain advantages compared to the 
traditional vehicles for treatment of scalp disorders. Negative sensory attributes 
such as greasiness, oiliness or tackiness can be to some degree avoided using 
foams as a vehicle for drug delivery. There is no sticky feeling and shiny look of 
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the hair after the application. Moreover, foams absorb and penetrate quickly 
without leaving any greasy residue on the hair bearing surfaces (Prudon et al., 
2003). 
Foams as low-residual vehicles can also be applied and spread more easily to the 
hair bearing skin than ointments or cream formulations. These vehicles break 
down rapidly during application and reach the Stratum corneum (SC) through 
the hair shafts. Foam density is approximately one tenth of the density of 
conventional vehicles. Therefore, foams can be applied and spread more easily 
onto large areas with less mechanical shearing compared to application of 
traditional vehicles. Feldman et al. (2000) showed with a ’’fingertip units test’’ 
that topical foam vehicles offer similar coverage compared with traditional 
vehicles. As low mechanical work is required, foams can be applied to sensitive 
or to highly inflamed skin, when it may be too painful or cause further 
inflammation if the formulation is rubbed onto the skin. 
Moreover, these application advantages for the scalp can be transferred when 
using foams to other haired body regions such as abdomen and chest for the 
treatment of corticosteroid responsive dermatoses. Because of evaporation of the 
solvent, foams are likely to be cooler than the ambient air, offering a cooling 
effect to an inflamed skin (Bikerman, 1973). 
In spite of the described cosmetical problems of drug delivery to the scalp and 
the fact that foams represent optimal delivery vehicles for this application site, 
there are only two foam formulations which are commercially available on the 
German market. These formulations have been successfully used not only in the 
treatment of pathological scalp conditions, but also corticosteroid responsive 
dermatoses of other body regions. 
Clarelux® foam formulation containing 1% clobetasol propionate (CP) is 
available on the German market from Pierre Fabre Dermo-Kosmetik since 2006. 
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Deflatop® from Astellas Pharma is a second foam formulation on the German 
market containing betamethasone valerate (BMV) at a concentration of 0.1%. 
Both formulations represent pressurized foam formulations which require the 
use of a propellant for foam generation. The use of propellants is considered to 
be the major disadvantage of aerosol foam formulations, as the propellant 
technology is relatively complex and expensive to manufacture and, therefore, 
increasing the overall cost of the product. The production expense of this type of 
formulations is a major factor that limits the number of foam formulations 
available on the market nowadays (Prudon et al., 2003). Both formulations also 
contain ethanol as a solvent which is considered unsuitable for sensitive and 
inflamed skin. 
Although there is few clinical evidence that foam formulations are currently 
superior to other conventional delivery vehicles, these formulations have a clear 
application advantage for patients, resulting in increased compliance. The study 
of Housman et al. (2002) showed that patients prefer foam and solution vehicles 
over creams, gels and ointments. Patients reported to prefer foam formulations 
because they are easier to use and are absorbed faster than other vehicles. The 
other study showed that twice-daily application of BMV foam was well 
tolerated and compliance exceeded 90% (Elewski et al., 2007). 
In spite of these positive facts raised from clinical experience, from the galenical 
point of view the formulation approach of these foams can not be considered as 
ideal. Both formulations contain ethanol which is used as a solvent for the active 
ingredients. Application of this excipient on the highly inflamed skin is not 
considered as harmless, leading additionally to skin dryness and irritation. 
Ethanol in these formulations may also affect drug penetration through the SC 
and may increase the corticosteroid penetration through epidermis leading to 
higher rates of systemic absorption. This is in contrast to traditional topical 
vehicles which rely on hydratation of the intercellular spaces in the SC to 
achieve drug delivery (Huang et al., 2005). Rapid evaporation of ethanol can 
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also influence the rate of drug transfer from the vehicle into the skin, as the rate 
of drug transfer is proportional to its degree of saturation in the vehicle at the 
vehicle-skin interface (Prudon, et al., 2003).  
In vitro permeation studies are an important step in the development of new 
topical vehicles to evaluate the absorption, penetration, bioavailability and, 
therefore, the potency of the drug for topical application. 
The first step to study the bioavailability of a topical formulation starts with in 
vitro tests. These tests offer a prescreening for later in vivo release studies. For 
in vitro permeation studies, human or animal full thickness skin, dermatomized 
skin or excised SC as a main barrier for drug penetration can be used (Dreher et 
al., 1996 and Dreher et al., 1997). Such studies can also be carried out using 
artificial membranes such as cellulose acetate or cellulose nitrate membranes. 
These membranes may be saturated with lipophilic liquids, such as isopropyl 
myristate, to simulate the barrier function of the SC (Csóka et al., 2001). This 
approach to characterize galenical formulations allows the prediction of the drug 
penetration depth and drug absorption. 
The growing interest in the development of foams for drug delivery rises the 
necessity to characterize these new vehicles for e.g. foamability of the 
formulations, foam stability and firmness which is an important step in the 
formulation development. However, suitable in vitro methods for foam 
characterization are currently lacking. 
The European Pharmacopoeia in the monograph ’’Medicated Foams’’ (Musci 
medicati) suggests two characterization methods. These are, firstly, the 
estimation of the relative foam density as an indication of the foam firmness 
and, secondly, the foam expansion time as a parameter for the foamability of the 
formulation. Specifically, the latter method is inapplicable for foams generated 
via other generation methods than pressurized foams. Furthermore, the 
determination of the foam stability is not considered in this monograph.  
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The assessment of the “before-application” stability is crucial for the pre-
formulation development stage independent from the foam generation 
mechanism. Moreover, an assessment of the general appearance as well as the 
stability and the intensity of expansion are important factors for the cosmetic 
acceptability of foams.  
 
1.2 Objectives 
The objective of this work was to develop a comprehensive approach to foam 
characterization as an alternative and supplement to the methods suggested by 
the Ph. Eur.  The methods should be also applicable for the characterization of 
propellant-free formulations in terms of their foamability, foam stability and 
foam firmness.  
Further aim of this work was to develop foamable formulations applying two 
different foam generation mechanisms. The first approach was to use a 
propellant-free foam generation mechanism. The Airspray® foam dispenser 
should be used for foam generation and be investigated for the delivery of 
pharmaceutical foams for dermal application. The foamable formulations to be 
developed should represent an advanced vehicle for topical drug delivery in the 
treatment of corticosteroid responsive diseases of the haired body regions such 
as psoriasis or seborrheic dermatitis. Abdication of propellants leads to 
reduction of production cost and to reduction of production time, omitting a 
process of propellant fill.  
The second approach was to develop a foamable formulation in pressurized 
containers using an alkane blend as a propellant. The target formulation should 
be alcohol-free to avoid enhancer properties of the formulation for drug 
permeation through the skin and decrease, in this way, possible side effects 
caused by systemic drug absorption. This foam should be applied during the day 
to the scalp improving cosmetic acceptability or should be used instead of a 
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shampoo. If the formulation is applied as a shampoo, a relative high amount of 
surface active substances should be present in the formulation.  
Both vehicles should be used for topical delivery of e.g. corticosteroids, 
antimycotics or anti-inflammatory agents. Corticosteroids, as many other topical 
therapeutic agents, are poorly soluble in aqueous vehicles. Therefore, most of 
the vehicles containing corticosteroids contain a lipophilic compound or organic 
solvent as e.g. ethanol. The aim of this work was to develop an innovative 
formulation platform to facilitate incorporation of steroids into an ethanol-free 
vehicle, containing no or only a small amount of lipophilic components.  
Two approaches were used for the formulation development: firstly, a foam on 
the base of an o/w emulsion with a low oil phase fraction and solubilized active 
ingredient and, secondly, a solution-based foam. Betamethasone valerate was 
used as a model substance. Solubilization of the active ingredient in the vehicle 
may have a positive effect on the drug release profiles in comparison to that of a 
dissolved or suspended drug. In case of the solution-based foam, betamethasone 
valerate is dissolved in the vehicle. Topical availability of betamethasone 
valerate from the newly developed vehicle was investigated by in vitro 
permeation studies.  
Another important aspect of this work was to investigate the release of 
betamethasone valerate from the developed formulations using artificial 
membranes and permeation of betamethasone valerate across animal or human 
skin. Deflatop® foam (Astellas Pharma) and Betagalen® lotion (Galen Pharma) 
were used as benchmark for a marketed ethanol containing foam formulation 
and a formulation in a conventional vehicle. The developed formulation should 
show at least similar release and permeation profiles or be superior compared to 
these commercial formulations.  
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2 Theoretical background 
2.1 Foams 
2.1.1  Definition 
A foam is commonly defined as a dispersion of gas in a liquid or a solid, 
whereas the volume fraction of gas in the foam is mostly between 0.5 and 0.9. 
The bubble size is typically between 0.1 and 3 mm (Wilson, 1989). The 
European Pharmacopoeia comprises a monograph called ’’Medicated Foams’’ 
(Musci medicati) which defines a foam as ’’formulation consisting of a large 
amount of gas dispersed in a liquid phase’’. 
 Foams can be classified into 2 types: liquid and solid foams. Solid foams can be 
generated when the liquid phase is transformed into a gel or solid phase after 
foam formation. These systems are also known as dry foams, xerogels or 
sponges and are often used as sore cover materials. They may contain 
disinfecting agents, antibiotics or steroids. Mostly, collagen or gelatin sponges 
which can absorb a lot of ichor because of their high capillarity are used. These 
materials are also available for temporary skin replacement after burn or in 
cosmetic surgery (Bauer et al., 1999). Furthermore, solid foams, such as foam 
rubber and polyurethane foams, have great commercial importance (Bikerman, 
1973).   
Foams are thermodynamically and mechanically unstable systems (Wilson, 
1989). They are characterized by a vast interface which tends to reduce itself. 
There are two fundamental parameters determining the structure and behavior of 
foams as disperse systems: the volume fraction of gas which is known as the 
phase volume and the diameter of the bubbles. 
Foams, in common with emulsions, are colloids and are composed of two or 
three distinct phases: normally a hydrophilic liquid continuous phase with a 
foaming agent, throughout which a gaseous dispersion phase is distributed. 
There may be a third hydrophobic dispersed phase (Wijnen, 1997).  
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2.1.2  Foam structure 
The foam structure is, e.g., described by Bikerman (1973). The bubbles in the 
foam can be more or less homogeneously distributed. They can vary in size and 
shape ranging from almost spherical to irregular polyhedral, depending on foam 
generating method and on the employed excipients. Different parameters, such 
as nature and concentration of foaming agent, viscosity of the liquid phase, 
temperature and pH of the system, affect the foam structure. Foam generation 
conditions also affect foam appearance and, therefore, the stability of foam 
bubbles. At moderate gas phase volumes, the bubbles dispersed in the liquid 
phase are uniform and packed as spheres, whereas, at higher phase volumes, 
typically higher than 0.7, the air bubbles deposited close to each other start to 
deform themselves (Yoshimura, 1988) (Figure 1A and 1C). A polyhedral bubble 
shape with partly plane faces is a result of this deformation. The thin layer of the 
continuous liquid phase (film) separating the faces of two adjacent polyhedral 
bubbles are called lamellae while the thicker channels, where three lamellae 
meet, are known as plateau borders (Figure 1B), (Hansen and Derderian, 1976). 
Plateau, the blind physicist, was the first one who investigated these films 
(Bikerman, 1973). The thickness of lamellae can vary between 10 nm and 1 µm 
(List, 1985).  The size of air bubbles is proportional to the length of plateau 
borders. As the bubbles have the same size, their boundaries or lamellae meet at 
an angle of 120° (Wilson, 1989). The curvature of lamellae results in the 
occurrence of a region of low pressure at the plateau region (Hansen and 
Derderian, 1976). The liquid in the lamellae is fixed to the molecules of a 
foaming agent which is adsorbed at both surfaces of lamellae. This fixation is 
very critical; otherwise the liquid in vertical lamellae would drain immediately. 
It was shown that presence of a liquid crystalline phase in equilibrium with an 
aqueous micellar solution of surfactant improves the stability of the foams 
formed from a surfactant solution. 
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Addition of a reversed micellar solution (e.g. an organic solution) capable to 
solubilize the liquid crystalline phase of such a foam causes foam breaking 
(Friberg and Saito, 1976). In spite of the firm fixation, liquid tends to drain into 
the plateau border region from the lamellae, as the pressure within this region is 
lower than in air bubbles and in the lamellae. This process causes the lamellae to 
become thinner. Thin lamellae are unstable and rupture because their surface 
area is too large for their volume (Bikerman, 1973). The most obvious cause of 
foam stability was pointed out by Plateau; he called it surface viscosity. The 
essential idea is that each film is stratified and has a sandwich-like structure.  
The inner layer of such a film has the viscosity of the liquid in bulk solution but 
the two exterior layers (adjacent to the gas phase) are much more viscous 
(Bikerman, 1973). Foams have unique rheological properties. The bulk flow of 
foams is very different from that of either Newtonian (laminar or turbulent) 
fluids or ’’conventional’’ two-phase fluids (Wilson, 1989). Presence of a 
significant yield stress is required to cause the flow (analogous to semisolids) 
and there is a strong shear thinning behavior. These properties derive largely 
from the unique microscopic structure of foams (Yoshimura, 1988). 
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Figure 1 Schematic illustration of foam structures: 
  A. Polyhedral foam, phase volume > 0.7 
  B. Plateau border region 
  C. Foam, phase volume < 0.7 
 
2.1.3  Foaming agents and surface activity 
Presence of a foaming agent is essential for foam generation and stabilization. 
Foaming agents are amphiphilic substances: the hydrophilic part of a molecule 
is responsible for water solubility. When a foaming agent is added to water, the 
hydrophobic parts of a molecule arrange themselves in a way to minimize the 
area of contact with water. This leads to their orientation at the air-water 
interface and to formation of micelles in the bulk of liquid phase.  
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When a foaming agent is adsorbed to the air-water interface, the surface tension 
of water is lowered and the surface pressure is increased. The surface pressure is 
defined as the difference between the initial surface tension of the system and 
the surface tension after addition of a foaming agent. Therefore, this parameter 
indicates the activity of a foaming agent. Nevertheless, higher values for surface 
pressure and lower values for surface tension do not always lead to an increase 
of foam stability. For foam stability, the concentration of foaming agent in the 
adsorbed layer is more important (surface concentration of a foaming agent). 
The relation between surface tension and adsorption of molecules into the air-
liquid interface is given by the Gibbs equation (Equation 1), (Stricker, 1987). 
Adsorption in this case is defined as the amount of foaming agent per unit 
surface area compared to the amount of foaming agent molecules that would be 
present at the surface if this foaming agent would not have any preference to 
adsorb to the surface. 
dc
d
TR
c γ⋅⋅−=Γ          Equation 1 
Γ  - molecules adsorbed to interface, ( )mol  
γ - surface concentration of a foaming agent, ⎟⎠
⎞⎜⎝
⎛
2m
mol
 
c  - molar concentration of the foaming agent, ⎟⎠
⎞⎜⎝
⎛
L
mol  
   R  - gas constant 8.31, ⎟⎠
⎞⎜⎝
⎛
⋅ Kmol
Joule  
  T  - temperature, ( )K   
γ - surface tension of the liquid, ⎟⎠
⎞⎜⎝
⎛
m
mN   
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dc
dγ  - decrease in surface tension caused by increased concentration 
of foaming agent, ⎟⎠
⎞⎜⎝
⎛ ⋅⋅
mol
LmmN   
The Gibbs equation is based on a dynamic equilibrium between the adsorbed 
and dissolved amount of foaming agent molecules. Adsorption of foaming agent 
is, therefore, reversible. But due to their extreme high surface activity, the 
molecules of the foaming agent are very hard to desorb by lowering for example 
their bulk concentration. Moreover, desorption of foaming agent molecules is 
slower, the higher the molecular weight and the more the surface tension is 
lowered. 
During foam formation, a rapid adsorption of the foaming agent is desirable. 
The rate of foaming agent adsorption depends on its diffusion rate. The diffusion 
rate of a foaming agent is given by the Fick’s law of diffusion (Equation 2) and 
the Einstein-Sutherland equation (Equation 3), respectively (Wilson, 1989). 
dx
dcAD
dt
dm ⋅⋅−=
         Equation 2 
Nr
TRD ⋅⋅⋅⋅
⋅= ηπ6          Equation 3  
dt
dm  - diffusion rate, ⎟⎠
⎞⎜⎝
⎛
s
mol  
D - diffusion coefficient, ⎟⎟⎠
⎞
⎜⎜⎝
⎛
s
m2   
A  - diffusion area, ( )2m   
 
dx
dc
  - concentration gradient, ⎟⎠
⎞⎜⎝
⎛
⋅mL
mol  
R  - gas constant 8.31, ⎟⎠
⎞⎜⎝
⎛
⋅ Kmol
Joule   
T  - absolute temperature, ( )K   
η  - dynamic viscosity of the solvent, ( )smPa ⋅   
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r - hydrodynamic radius of molecule, ( )m   
N - Avogadro number ( )1231002.6 −⋅ mol  
The thickness of the solution layer that can provide the surfactant to adsorb to a 
surface and the concentration of foaming agent in the bulk of the liquid 
determine the diffusion rate of molecules towards the interface. Foaming agents 
may also be transported from one site of the surface to the other by spreading, if 
it is unevenly distributed. The spreading rate is much slower than the mixing 
speed. The rate of foaming agent adsorption depends on its concentration and 
agitation in the bulk of liquid and is critical for foam formation. During foam 
formation, concentration of the foaming agent in the bulk phase will decrease 
with the increase of the created surface area. The higher the volume fraction and 
the smaller the air bubbles, the larger the created surface area will be. Reduction 
of the foaming agent concentration in the bulk solution leads to a decrease of the 
concentration gradient and diffusion rate. Therefore, to assure a rapid diffusion 
of a foaming agent to the surface, a high foaming agent concentrations and a low 
viscosity of the liquid phase are needed. The ratio between the free energy of 
adsorption of foaming agent to the surface of the solution and the free energy of 
micellisation of it in the solution are convenient criteria for estimation of 
foaming power for a foaming agent (Skrylev et al., 1985). 
There are three stages of foam generation: 
- production of a solution of foaming agent (without incorporated air) 
- ’’emulsification’’ of gas (solution starts to incorporate air, at lower 
volume fractions, air bubbles do not have contact to each other; no 
influence on bubble geometry) 
- foam formation (polyhedral foam, air bubbles have contact to each other 
through lamellae, their spherical geometry is disturbed). 
In a homologous series of foaming agents the maximum of foaming ability is 
observed at a concentration equal to, or near to, the critical micelle concentration 
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(Bikerman, 1973). A combination of two foaming agents can either lead to a 
faster foam generation and increased foam stability or to a decrease in foam 
stability. Also, the salt concentration of the solution may influence the process 
of foam generation (Jellinek, 1959).  
Foam boosters are substances which enhance foam formation. The majority of 
these substances are from the chemical group of fatty acid alcohol amides, e.g. 
oleic acid diethanol amide, coco fatty acid diethanol amide, polycarboxylic acid 
poly diethanol amide. They are normally used at a concentration of 5%, 
otherwise skin irritation is likely to occur (Nowak, 1969).  
Addition of some polymers to foamable formulations can lead to increased foam 
stability. For example, it was shown that the addition of polyacrylic acid to non-
ionic surfactants leads to the formation of a surfactant-polymer complex through 
interactions between polymer and surfactant, contributing to the foam stability 
(Zhukov et al., 1987). Polymers such as cellulose derivatives or xanthan gum 
are also used to increase foam stability.  
It is known, however, that addition of small quantities of specific agents to 
foaming systems can cause a reduction of the stability of formed foams 
(Table 1). These agents can be divided into two types. The first, foam 
destroyers, are added to existing foams, and they are generally considered to act 
in the form of small droplets, spreading on the foam lamellae. By this, lamellae 
are thinned and the foam breaks. These substances (e.g. oils, alcohols or organic 
solvents) are normally poorly soluble in water. They orientate themselves at the 
surface, leading to an increase of surface pressure and a reduction of elasticity of 
the surface film formed by a foaming agent. The presence of oil droplets in the 
system leads to change of the surface tension and to an increased liquid drainage 
causing the rupture of the lamellae. Foam inhibitors, on the other hand, are 
generally believed to have a good affinity to the air-water interface. 
 
 
2 Theoretical background 
 21
Table 1 Excipients for foam production / foam destruction  
Foaming agents Foam stabilizers Foam 
destroyers 
Foam 
inhibitors 
Surfactants, e.g. 
Sodium stearate 
Sodium oleate 
Sodium dodecyl sulfate 
Dioctyl sulfosuccinate 
 
Proteins, e.g.  
Collagen 
Hydrocolloids, e.g. 
Xanthan gum 
Hydroxypropyl methyl 
cellulose 
Methyl cellulose 
Alginates 
Agar-agar 
Arabic gum 
Oils 
 
Alcohols 
 
Solvents, e.g. 
Acetone 
 
Silicon oils 
 
Glycerides 
 
 
 
They adsorb at the interface in preference to the foaming agents and, by this, 
prevent foam generation (Roberts et al., 1975). Addition of some electrolytes to 
the foaming solution can lead to changes in foaming capacity (Nakagaki, 1950). 
Presence of poorly wettable solid particles can also lead to the rupture of 
lamellae. If a film is sufficiently thin for a particle to bridge it, and if the 
material of the particle is sufficiently hydrophobic, the Laplace pressure in the 
film next to the particle may become positive. This would cause liquid to flow to 
a region of lower pressure, and, thus, leading to film rupture (Wilson, 1989).  
 
2.1.4  Production of foams 
Foams can be produced by mechanical means or by supersaturation of the liquid 
phase with gas (Wilson, 1989). Liquids can be supersaturated with gas either by 
dissolving gas under pressure or by gas formation in situ. Nucleation of gas 
bubbles in this case is the critical process.  
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2.1.4.1 Whipping 
Whipping or beating can be carried out with different devices that agitate a 
liquid in order to form an interface with the gas phase. This method is a standard 
method of gas introduction to a liquid. The volume of the air incorporated into 
the foam usually increases with an increase of beating intensity, whereas beating 
of a high viscous liquids leads to the generation of unstable foams. Every air 
bubble undergoes severe mechanical stresses through whipping, therefore, a 
more rapid coalescence happens during foam generation compared to a standing 
foam. Final foam volume is a result of dynamic equilibrium between mechanical 
air bubble formation and bubble destruction. The mechanical stress also leads to 
the destruction of bigger air bubbles into smaller ones. Foam generation by 
whipping is used in food industry for production of e.g. whipped cream, instant 
puddings or toppings (Wijnen, 1997). 
 
2.1.4.2 Shaking 
This method is used rarely. The rate, at which air bubbles are introduced to a 
solution, depends on the frequency and amplitude of shaking, the volume and 
shape of container and the volume and viscosity of liquid. Only low foam 
volumes with long generation times can be produced by this method. 
 
2.1.4.3 Bubbling 
By bubbling, foams are generated by injection of gas through narrow openings. 
This method is reproducible and gives uniform bubble sizes. The volume of 
foam produced by this method depends on the total amount of foaming agent in 
the solution being bubbled. 
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2.1.4.4 Pressurized aerosol foams 
Aerosol foam formulations represent a range of dosage forms that have achieved 
international commercial success as innovative cosmetic vehicles in the recent 
years. 
There are two types of aerosol foams: two-phase and three-phase aerosol foams 
(Jellinek, 1959). 
In two-phase (Figure 2A) systems the liquefied propellant is solved in the 
solution of a foaming agent under pressure. The aerosol can contains a 
continuous liquid and a gas phase. The liquid phase consists of a solvent, 
foaming agent and foam stabilizer, whereas the gas phase is composed of 
propellant vapor. The gas phase practices pressure on the aerosol can containing 
the fluid phase which is always higher than the atmospheric pressure. This 
pressure is dependent on the composition of the propellant in the system and is 
typically in the range of 2 - 4 bar. When the nozzle of the spray head is opened 
connecting the interior with the external air, the fluid phase will be forced out of 
the aerosol can through an orifice. At atmospheric pressure, the liquefied 
propellant evaporates instantaneously, generating a foam (Mueller, 1998). Foam 
formation is supported through specific foam actuators placed to the outlet of the 
can.   
Three-phase systems (Figure 2B) are for example o/w emulsions (Voigt, 2006). 
The propellant is solved in a lipid phase which is emulsified into a water phase 
through addition of an emulsifier. The foaming agent can also act as an 
emulsifier. The third phase is the vapor phase of the propellant above the 
emulsion. Both two-phase and three-phase systems should be shaken before 
actuation. The velocity of foam generation is dependent on the rate of propellant 
evaporation. Propellants with low boiling points evaporate rapidly leading to 
immediate foam generation. If the propellant blend also contains a component 
with a higher boiling point, this leads to a delayed foam generation. Water is the 
most frequently used solvent in foam aerosols. Beside water, ethanol and 
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isopropanol are occasionally used as solvents. Many pressurized aerosol foams 
can be mixed in cold state. But more often the oil phase should be warmed up to 
70 to 80°C and brought into the liquid state. The aqueous phase, with water 
soluble ingredients has also to be brought up to the same temperature and 
subsequently mixed into the oil phase. Temperature sensitive ingredients, such 
as extracts and vitamins, can be introduced after cooling down to 40°C. Finally 
the product has to be homogenised. The production is carried out under vacuum 
where foaming can be avoided (Hoffbauer, 1996). Examples for this type of 
system are shaving foam, hair styling mousse, aerosol shampoo, aerosol hand 
cream and aerosol mask (Jellinek, 1959; Raab and Kindl, 1999). 
The formulation is filled into an aerosol package, comprising a can, valve and an 
actuator. The materials of aerosol cans can be aluminum or tin. Both of the 
metals can be incompatible with some solvents, therefore, the inside of the can 
is often coated with epoxide resins. A foam valve is crimped onto the aerosol 
can. Special foam valves are used for foam generation. Foam valves comprise a 
stem and can be produced with or without a metering chamber. These valves 
should have a special valve support being corrosion-resistant due to the presence 
of the water phase in the system (Voigt, 2006). The valve seal should be 
compatible with solvents, surface active substances and propellants used in the 
formulation. Foam valves are available e.g. from Lindal and Precision Valve 
(Kuplien, 1994). The foam actuator is fixed to the valve and has the function to 
dispense the aerosol foam. Foam actuators with upright orifice, two-piece 
actuators with a membrane or one-piece actuators to produce an improved foam 
quality can be used (Hoffbauer, 1996). 
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A. B.
Propellant vapor
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Propellant vapor
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  Aerosol can
Foam actuator
Dip tube
Foam valve
 
 
Figure 2 Aerosol foam products (adopted from Jellinek, 1958) 
A. Two-phase system 
  B. Three-phase system 
 
Using a spray actuator, spray foams may be produced. The nozzle geometry of 
an actuator has an effect on the appearance of the generated foam.  
After the valve has been crimped onto the aerosol can, the propellant is added to 
the aerosol container, either through the valve or during the crimping process. 
The most often used propellants are hydrocarbon propellants e.g. n-butane, 
isobutane and n-propane or mixtures thereof. These propellants are liquefied 
under pressure and their blends have a wide interval of boiling points. The 
concentration of the propellant in the aerosol can is typically in the range of  
3%-12% (Voigt, 2006). This amount of propellant is sufficient to produce a 
suitable quality of foam. There are systems which contain both primary 
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propellants, in the meaning of ’’immediately’’ evaporating propellants 
(e.g. compressed air) and secondary propellants (e.g. n-pentane, isopentane, 
isobutane) which evaporate with a delay, causing a cooling effect on the skin 
surface (Kroepke et al., 2004). Nitrogen, oxygen, helium, argon, dinitrogen 
oxide and carbon dioxide can as well be used as propellants. Hydrofluoroalkane 
propellants are also described for this application (Hirsh et al., 2005).  
 
2.1.4.5 Bag-in-can system 
It is also possible to formulate a semi-solid gel system that foams when it is 
rubbed on the body. These products usually contain a low-boiling hydrocarbon 
such as isopentane which has a boiling point of about 28°C. Application and 
agitation of such a product at body temperature causes the isopentane to 
vaporize and generates a foam with similar properties than a pressurized aerosol 
foam system. Because of the low boiling point of isopentane, these formulations 
are also packaged in pressurized containers but a barrier system separates the 
product with solubilized isopentane from the pressurizing gas. The external 
pressure is needed to dispense the product and also to keep the isopentane in the 
product. The formulation is added to a bag and the system is pressurized from 
the bottom of the can and then sealed with a plug (Schlesinger, 2000). Such 
systems are available from e.g. CCL Container (USA). 
 
2.1.4.6 In situ gas generation 
The gas which is needed for foam production can as well be generated in situ as 
e.g. in vaginal and rectal foams and tablets. Through the contact with mucosal 
secretions the gas is generated, leading to foam production (Friess et al., 1999). 
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2.1.5  Foam stability 
’’It is perhaps surprising to find in 1958 that no thoroughly satisfactory 
explanation have been given to why certain liquids foam strongly, others feebly, 
and many not at all’’ (Exerova et al., 1975). Nowadays it is almost true to use 
the same sentence. In spite of many investigations it is very difficult to develop 
a general theory of foam stability as many different, both dynamic and static 
factors determine it. 
If the film between two bubbles ruptures, the bubbles will coalesce. The stability 
of foams has been, therefore, related to the colloidal stability of these thin films. 
The stability of the films is dependent among others on van der Waals’ attractive 
forces and the electric double-layer repulsion potential (Friberg and Saito, 
1975). 
Several different processes can be identified in the breakdown of foams 
(Wijnen, 1997). These are:  
- disproportionation (Ostwald ripening),  
- gravitational separation (creaming, bubble rise and drainage) and  
- encounter mechanism (Brownian motion) (Figure 3).  
These processes happen to a considerable extent simultaneously, enhancing each 
other. This leads to many possible intermediate stages between a uniform 
dispersion and two completely separated phases. As soon as bubbles are formed, 
several changes start to occur. The pressure inside the air bubbles is higher than 
that in the solution or air. This pressure increase can be described by the Laplace 
equation (Equation 4) (Bikerman, 1973).  
Moreover, the pressure and the solubility of the dispersed air phase are greater 
for smaller bubbles. This creates a driving force for diffusion from small air 
bubbles to larger ones or to the bulk liquid phase. The rate of diffusion depends 
on the solubility of the dispersed air phase in the continuous liquid phase. 
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d
P γ4=Δ
          Equation 4 
−ΔP  pressure difference,  ⎟⎠
⎞⎜⎝
⎛
2m
N  
−γ  surface tension of the liquid, ⎟⎠
⎞⎜⎝
⎛
m
mN   
−d diameter of the bubble, ( )m  
 
 
Gravitational separation
(creaming)
Foam
Coalescense as a result 
of lamellae rupture
Reformation to
polyhedral foam
Disproportionation
(Ostwald ripening)
 
Figure 3 Mechanism of foam destabilization (adopted from Oungbho, 1997)  
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That is the reason for Ostwald ripening of foam bubbles (Wilson, 1989). As a 
result of this destabilization mechanism, the smaller air bubbles dissolve while 
bigger bubbles grow in size by gas diffusion through the liquid phase (Hansen 
and Derderian, 1976). Because of a density difference between the phases, 
gravitational and capillary forces cause a flow of the continuous liquid phase 
around the dispersed air bubbles. The air bubbles move towards the top while 
the gravitation forces lead the liquid to drain within the foam lamellae. At low 
gas volume fractions, the creaming mechanism of foam destabilization 
predominates whereas at higher gas volume fractions the liquid drainage 
prevails (Wilson, 1989).  
The liquid drainage leads to generation of a foaming agent concentration 
gradient within the lamellae and, therefore, a surface tension gradient. This 
gradient can be stabilized through the adsorption of foaming agent from the bulk 
solution. Nevertheless, both of these processes cause segregation of the foam 
into the foam layer on the top and drained liquid layer on the bottom. 
Foam drainage is a complicated process that is not fully understood. The flow 
through individual channels depends on the type of surfactant used to create the 
foam (Koehler et al., 2004). 
The drainage is completely independent from bubble rupture (Bikerman, 1973). 
The reason for a bubble rupture is an insufficient elasticity of the surface film. 
Under elasticity one can understand the ability of lamellae to stabilize 
themselves when through the liquid drainage the concentration of the foaming 
agent at the surface becomes inhomogeneous. Liquid drainage can also cause 
increase of air bubbles size without a collapse. When the film is elastic, it means 
that the liquid with foaming agent is transported to the place of the possible 
rupture (’’closing the wound’’). This effect is called Marangoni effect (Ross and 
Nishioka, 1975). The Marangoni effect is generally believed to be the main 
cause of film stability. 
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2.1.6  Foam stabilization 
Foams with a higher gas volume fraction are more stable. In this case, liquid 
drainage as well as creaming is delayed. Higher concentrations of a foaming 
agent are also advantageous, leading to a higher elasticity of the surface film. 
Creaming and foam drainage depend on the solution viscosity. Therefore, higher 
viscosities could lead to a delay of phase break-up. In this case, the use of 
thixotropic substances is beneficial. Arabic gum, methyl cellulose and similar 
hydrophilic materials of high molecular weight raise the stability of foams due 
to an increase in viscosity (Bikerman, 1973). Temperature also affects the rate of 
drainage by altering the liquid bulk viscosity. The DLVO-theory also can be 
used to explain foam stabilization. When a substance is added to foam leading to 
a charge of the surface film, this can result in repulsion of the air bubbles 
coming close to each other. Electrostatic or steric stabilization can be achieved 
through the use of macromolecules in the formulation. The macromolecules 
orientate themselves at the surface and, therefore, can provide a steric 
stabilization, hindering the air bubbles to coalesce. 
 
2.1.7  Characterization of foams 
Macroscopic processes of foam destabilization correspond directly to the 
microscopic processes described above. Collapse of the foam column leads to a 
decrease of foam volume which happens essentially through loss of gas. The 
problems of measuring foam stability depend first of all on the insufficient 
characterization of these processes. Whereas the increased volume of drained 
liquid is easy to measure, the coalescence e.g. of the air bubbles can not be 
measured this easy. 
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2.1.7.1 Methods of the European Pharmacopoeia 
The European Pharmacopoeia (Eur. Ph. 6.0) describes two characterization 
methods for foams in the Monograph “Medicated foams”: determination of 
relative foam density and foam expansion time.  
Density of produced foams is determined by weighing a predefined volume of 
foam compared to the weight of the same volume of water (Equation 5). 
)(
)(
waterm
foammFD =         Equation 5 
( )foamm  - mass of foam per volume unit, ( )g    
 ( )waterm  - mass of water per volume unit, ( )g  
For determination of foam expansion time, a foam volume is fed in a burette and 
foam expansion is followed within a defined time. 
 
2.1.7.2 Additional methods 
Some additional methods for foam characterization are described in literature. 
One method to measure foam consistency is described by Mitkevich (1952). The 
foam in this case is produced in a vertical cylinder vessel provided with a small 
indentation in the center of its base. The rounded end of a glass rod is placed in 
this indentation and the rod is held vertically by an upper support. Withdrawal of 
the support allows the rod to fall against a wall of the vessel. The time of fall is 
used empirically as a measure of foam consistency. Further methods to measure 
foam consistency such as determinations with a mobilometer, foam 
consistometer and Brookfield viscosimeter are described by Scott and 
Thompson (1952).  
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2.1.7.3 Macroscopic evaluation 
Foams can be characterized macroscopically, with the determination of 
descriptive parameters as being fine pored or coarsely porous, viscous or runny. 
 
2.1.7.4 Foam bubble size / Microscopic evaluation and Image Analysis 
System 
Bubble size and structure of generated foams can be observed and measured 
with a stereo microscope connected with a digital ocular. Foam uniformity can 
also be determined with this method as homogeneity of air bubbles. The major 
disadvantage of this method is, however, that the resolution of these 
observations is severely limited by the wavelength of visible part of the 
spectrum. Because of the large semi-aperture angle, they have a small depth of 
field which reduces the potential for stereo observations of the highly three-
dimensional foamed materials (Wilson, 1989). 
Produced foams can also be analyzed by means of an Image Analysis System 
(e.g. Sympatec GmbH, Germany). The size (Ferret diameter), roundness and the 
aspect ratio of incorporated air bubbles as well as bubble amount in a predefined 
area are the parameters of interest. Measurements can be carried out directly 
after foam generation and after defined time intervals to follow the foam 
destabilization mechanisms allowing for a foam stability assessment. 
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2.1.7.5 Rheological properties 
Rheological properties of foams are very difficult to measure, especially for 
weak foams. First of all, foams are unstable because of liquid drainage and 
Ostwald ripening. Additionally, the generation of a liquid film slip layer at the 
wall during the measurement will affect its accuracy (Mleko et al., 2007). 
However, rheological methods may be used in oscillatory mode to learn about 
foam film elasticity and, therefore, foam stability. 
 
2.1.7.6 Foamability measurements in cosmetic formulations 
The test most often used for measurements of foaming capacity of cosmetic 
formulation is the test of Ross and Miles (Jellinek, 1959). This test is based on 
the fact that the volume of foam is an approximately linear function of the height 
of fall and that the various materials differ in the stability of their foams and not 
in their capacity to foam (Nowak, 1969).  The test liquid with a foaming agent is 
filled into a pipette of a defined geometry and dropped through a pipette 
aperture into a container which also contains the test solution. The volume of the 
foam, generated under these conditions is measured directly after generation and 
after 5 min to evaluate the stability of the foam column. 
A faster screening method to compare foam generation characteristics of 
different foaming agents is to fill the solutions into a graduated cylinder and to 
measure the height of the foam column after shaking and after 5 min (Jellinek, 
1959). 
A rotor-test can also be used for a quick and reliable assessment of foam kinetics 
of test solutions with and without addition of defoaming agents. The solution of 
the foaming agent is thermostated in a cylindrical vessel with a water jacket. A 
stirrer is immersed into the solution whereas the revolutions per minute of the 
stirrer are set. During foam generation the foam height is recorded every 10 s 
within 3 minutes (Engels et al., 1998). 
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The Schlachter-Dierkes and Colson tests are based on the fact that presence of 
fat leads to a worsening of the foaming capacity. During these tests the height of 
a foam column generated from a test formulation without fat contamination by 
beating is compared to a height of a foam column after addition of a defined 
amount of a defined fat blend to the same formulation (Nowak, 1969).  
During the Wilmsmann test the rate of foam generation (foam ’’boost’’), foam 
stability and foam drainage are tested in a special device with and without fat 
contamination (Nowak, 1969).  
Wehle (1957) has proposed a method to measure the foam strength of tooth care 
products by determination of a foam strength number by means of the foam 
height before and after shaking.   
With the SST-test (stress-stability test) the mechanical stability of foams can be 
measured. The foam of the test solution is generated in a cylindrical vessel with 
a thermostated water jacket by means of nitrogen gas passing through a very 
fine metal sieve. After 2 min the gas flow is stopped and an aluminum plate with 
a definite weight is placed on top of the foam column. The plate compresses the 
foam and passes down to the bottom of the vessel destroying the foam. The 
height of the plate as a function of time is a measure of the foam stability 
(Engels et al., 1998). 
The half-head-test is a clinical one-to-one comparison under realistic conditions 
for hair shampoos. In this case, two products are applied on each of the two 
hemispheres of the head of a test person. Parameters such as feel of the foam as 
well as feel of the wet and dry hair, visual appearance and rinse-off 
characteristics of the foam are evaluated by a group of five experts (Engels et 
al., 1998). 
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2.1.8  Pharmaceutical foams 
The interest in the development of new vehicles for topical delivery is steadily 
growing nowadays. Foams represent one option of such new pharmaceutical 
vehicles. Depending on the way of pharmaceutical application rectal, vaginal 
and dermal foams can be defined.  
Foams for dermal drug delivery have some advantages compared to the 
traditional vehicles for treatment of topical disorders such as ointment, creams, 
lotions, gels or solutions. Vaginal and rectal foam vehicles also feature some 
application advantages compared to the standard vehicles such as suppositories, 
creams and ointments. Foam vehicles require a ’’one step’’ administration, they 
are convenient to insert, and no leakage of the vehicle takes place during 
application. Moreover, the residence time of the active pharmaceutical 
ingredients can be controlled through the use of bio-adhesive polymers. 
There are also nasal compositions containing foaming agents such as saponin 
and lecithin under development which should moisturize the nasal cavity in 
treatment of rhinitis. Nasal foams containing non-steroidal anti-inflammatory 
and analgesic agents for treatment of low back pain, arthralgia, distorsion and 
tendosynovitis (Nakagawa et al., 1991) are also described. 
 
2.1.8.1 Dermal foams 
Dermal foams can be used in the treatment of different skin conditions, as for 
example seborrheic dermatitis (SD).  
Extina® foam developed by Connetics Corporation (USA) is a foam containing 
2% of ketoconazole for the treatment of mycoses and other dermatological 
indications, particularly SD which was approved by FDA in 2007. This product 
utilizes Connetics’ proprietary foam drug delivery technology - Versa Foam 
HFTM (hydroethanolic formulation) technology (Popp et al., 2004). This foam 
was proven to be an effective and safe topical therapy for mild to severe SD, 
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significantly relieving symptoms after 4 weeks of therapy (Rolz-Cruz and 
Kimball, 2008). Extina® foam proved to be superior to placebo foam in phase III 
clinical trials and equivalent to ketoconazole cream. Moreover, patients reported 
to prefer foam formulations because they were easier to use and were absorbed 
faster than other vehicles (Elewski et al., 2007). The most frequently reported 
adverse events in the ketoconazole foam group were application site reactions 
which were generally mild and transient (Koller et al., 2004). In the treatment of 
dandruff, the foam containing ketoconazole was shown to be as effective as 
ketoconazole 2% lotion (Milani and Quadri, 2004). 
More foam products from Connectics Corporation and Stiefel Laboratories are 
available on the US dermatology market, such as Evoclin® clindamycin 
phosphate foam, 1%; Olux® and Clarelux® clobetasol propionate (CP) foams, 
0.05% and Luxiq® betamethasone valerate (BMV) foam, 0.12%. 
Clarelux® foam is indicated for short-term topical treatment of inflammatory and 
pruritic manifestations of corticosteroid-responsive dermatoses of the scalp and 
plaque-type psoriasis of non-scalp regions excluding face and intertriginous 
areas. Deflatop® foam is used in the treatment of head skin diseases which are 
responsive to corticosteroid therapy such as psoriasis or Alopezia areata. 
The CP foam was shown to be safe and effective for the treatment of plaque 
type psoriasis of scalp and nonscalp areas when applied twice daily for two 
weeks (Lebwohl et al., 2002; Gottlieb et al., 2003; Reid and Kimball, 2005). 
The studies of Franz et al. (2000) and Bergstrom et al. (2003) showed that CP 
foam was superior to a currently marketed solution, cream and lotion vehicle in 
terms of improvement of psoriasis severity. Patients also indicated to spend less 
time applying foam vehicle compared to solution and cream. Moreover, CP 
foam and BMV foam were shown to be effective in improving Acne keloidales 
in an open label study (Callender et al., 2005).  
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The foam containing BMV was shown to be more effective than the standard 
therapy (corticosteroid and calcipotriol lotions) commonly used in the treatment 
of scalp psoriasis. This vehicle was considered to be better than a lotion in terms 
of application convenience, leading to superior patient acceptability and a 
positive effect on the Psoriasis Disability Index (Andreassi et al., 2003). 
Moreover, the BMV foam was effective in the treatment of scalp psoriasis with 
both once-a-day and twice-a-day application (Feldman et al., 2001). BMV foam 
was also shown to be effective against nonscalp psoriasis (Stein et al., 2001) and 
in the short-term treatment of seborrheic dermatitis (Massimo et al., 2003). 
Mancuso et al. (2003) considered BMV foam to be effective and well-tolerated 
in the treatment of mild-to-moderate Alopezia areata. A combination of BMV 
foam (in the morning) with tazarotene cream (in the evening) was shown to be 
an effective approach to treat localized plaque type psoriasis (Dhawan et al., 
2005). The study of Melian et al. (2001) and Stein (2005) showed that BMV 
foam and CP foam were absorbed more rapidly and demonstrated greater total 
absorption than their respective comparison formulations, namely BMV lotion 
and CP solution. The other study showed that although BMV bioavailability 
from the foam vehicle was increased, this was not associated with an increase in 
toxicity (Franz et al., 1999).  
Evoclin® foam is indicated for topical application in the treatment of Acne 
vulgaris. Luxiq® and Olux® foams are used for symptom relief of inflammatory 
state of corticosteroid-responsive dermatoses of the scalp including eczema, SD, 
psoriasis and contact dermatitis.  
A betamethasone valerate foam, 0.1% is also launched on the UK market by 
Mipharm under the trade name BettamousseTM. 
There are also products from Connetics Corporation which are still under 
development, such as ActinaTM, a foam formulation with clindamycin 
phosphate; DesiluxTM desonide foam, 0.05% - a low potency topical steroid 
formulated to treat atopic dermatitis and PrimoluxTM, a clobetasol propionate 
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foam, 0.05%. Clindamycin phosphate foam was shown to be at least as safe and 
effective as clindamycin phosphate gel (Shalita et al., 2005). 
Epifoam®, a combination of topic corticosteroid (hydrocortisone acetate, 1.0%) 
and local anesthetic (pramoxine hydrochloride, 1.0%) for treating inflammation 
and itching of the skin due to certain conditions, is available on the US market.  
Thiocolchicoside, a semi-synthetic derivate of colchicoside, is used in topical 
formulations for its anti-inflammatory and muscle-relaxant properties, has been 
also formulated as a foam formulation (Miotens®, Bonita et al., 2002). Ibuleve® 
Mousse with ibuprofen, 5.0%, is launched in the UK market. It should be 
applied for fast pain relief such as backache, rheumatic and muscular pain, 
sprains and strains and for pain relief in common arthritic conditions.  
Mipharm has also brought new synergized pyretrine foam for the treatment of 
scabies onto the UK market (Milice®). A pimecrolimus aerosol foam can be 
used for treatment of various skin, nail and mucosal diseases (Eini et al., 2005). 
There are also some foam products for disinfection. For example Soft’N SureTM 
antiseptic hand foam from STERIS is used for hand disinfection and contains 
62% ethyl alcohol and vitamin E as skin moisturizer. DesenexTM foam with 10% 
of undecylenate from Ciba Consumer is used as an antifungal and antibacterial 
product for Tinea pedis. SeptisolTM foam with 0.23% hexachlorophene from 
Calgon Vesal is used as bacteriostatic skin cleanser. BetadineTM foam from 
MundiPharma and OperandTM foam from Redi-Products containing povidone 
iodine are used as a shampoo to relief itching due to dandruff. 
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2.1.8.2 Rectal foams 
Rectal foams are mostly aerosol foams (Sachetto, 1996). Two rectal aerosol 
foams are present on the German market: Colifoam® with hydrocortisone 
acetate, 1% and Claversal® with mesalazine, 20%. The mesalazine foam is 
patented by Falk Pharma (Kuehn, 2003). Both are used for the treatment of the 
large intestine inflammation diseases Morbus Crohn or Colitis ulcerosa. The 
ease of retention and apparent nonabsorption of active component, leading to 
minimizing steroid side effects are the specific advantages of these formulations 
(Neumann et al., 1989; Hammond et al., 2004).  
 
2.1.8.3 Vaginal foams 
These are formulations containing spermicide substances which are used for 
local contraception. The foam in this case is generated in situ from a tablet 
containing an alkaline and an acidic component, e.g. sodium hydrogen carbonate 
and tartaric acid, by the contact with the cervical secretion.  
Patentex® Oval vaginal suppository from Merz Consumer Care with p-nonyl 
phenoxy polyethoxy ethanol represents such a formulation on the German 
market. This method of contraception combines the advantages of high 
contraceptive efficiency and good tolerance with no contraindications (Brehm 
and Haase, 1975). The aerosol foam containing p-nonyl phenoxy polyethoxy 
ethanol 80% and benzethonium chloride 0.2% showed a contraception rate of 
1.75 pregnancies / 100 woman year of exposure (Bushnell, 1965). There are also 
patents for a vaginal foam containing rifaximin for the treatment of vaginal 
infections (Marchi et al., 1993).  
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2.1.9  Cosmetic foams 
Over years foams have claimed their role in the cosmetic scene. Nevertheless, 
the addition of a foaming agent in e.g. tooth paste is discussed controversially as 
it leads to the development of a wrong psychical conjunction from the 
customers’ view between washing activity and the amount of generated foam 
(Charlet, 1989).   
In some cosmetic formulations, foam has also functionality, e.g. hard, fine pored 
shaving foam helps to uphold the hair during the shaving process. Hair mousse 
helps to give the hair desirable shape and volume (Umbach, 1988). Foam 
formation during the application of a foam bath or foam bath powder is only a 
cosmetic attribute. For foam baths some foam characteristics such as fast foam 
generation (’’flash foam’’), high foam volume, good stability of foam and slow 
foam drainage are especially desired.  For shampoos, good foamability of a 
formulation even under strong fat contamination is of specific importance 
(Nowak, 1969). There are also aerosol hair dyeing foams on the market. 
Cosmetic foaming compositions can contain keratolytics, lubricating agents, 
germicide agents e.g. triclosan (Paul, 2006) or sunscreens. Dry aerosol foams 
containing zeolite can be used as dry aftershave talc foam, dry deodorant foam, 
dry makeup foundation foam or dry body talc foam (Gupte and Bogardus, 
1987).  
There are also foam compositions for application to the skin as a barrier to skin 
irritants to prevent contact dermatitis caused for example by sodium lauryl 
sulfate. Such formulations, as e.g. a protective foam containing dimethicone and 
glycerine, were shown to improve chronic hand dermatitis in individuals with 
previously uncontrolled dermatitis despite continuing their regular occupation 
(Fowler, 2000).  
Bepanthen® is a foam formulation marketed in Germany by Roche Consumer 
Health Ltd containing dexpanthenol which is used to improve the healing 
process of the skin (Neubeck and Weber, 2004). Allpresan® is a trade name for 
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different foam formulations used to treat dry skin conditions which contain urea 
in different concentrations (5%, 10%, 15% and 18%). 
 
2.2 Human skin 
Human skin is an effective anatomical outer barrier of the body of 
approximately 1.5-2.0 m2 that separates the human organism from the 
environment. The skin functions are very multifaceted and can be separated into 
the following groups: human skin 
- plays a key role in protecting the body against external substances and 
pathogens, 
- regulates water evaporation and presents a protection for the body against 
excessive water loss and, therefore, helps to regulate temperature,  
- impacts to the sensation containing a variety of nerve endings that react to 
heat, cold, touch, pressure, vibration and tissue injury,    
- synthesizes vitamin D and 
- plays an aesthetic role (Braun-Falco, 2000).   
 
2.2.1  Structure of the human skin 
The structure of the human skin is described in detail elsewhere (Hornstein and 
Nuernberg, 1985; Niedner and Ziegenmeyer, 1992). 
The macroscopic structure of human skin can be divided into the following 
layers: epidermis, dermis and hypodermis (subcutaneous adipose layer). 
The epidermis is the outermost layer of the skin which contains no blood 
vessels. It is made up of a stratified squamous epithelium with the underlying 
basal lamina. The main cell types are keratinocytes and Merkel cells; 
melanocytes und Langerhans cells are also present. The epidermis can be further 
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subdivided into the following layers: Stratum corneum (SC), Stratum lucidum, 
Stratum granulosum, Stratum spinosum, Stratum basale. The keratinocytes are 
formed through mitosis in Stratum basale. They move up the layers changing 
shape and composition as they move away from the blood source; the cytoplasm 
is released and replaced by keratin. This process is called keratinisation and 
takes place within about 27 days. The structure of the SC is described by the 
’’brick-and-mortar-model’’. The unique lipid matrix of it consists of ceramides, 
cholesterol, cholesterol ethers and fatty acids. The thickness of the SC differs 
between different body regions (Charlet, 1989).     
The dermis is a layer of skin beneath the epidermis and connected to the 
epidermis by the Stratum basale. The dermis consists of connective tissue with 
collagen und contains blood and lymphatic vessels, hair follicles, sweat, 
sebaceous and apocrine glands. The main cells are fibroblasts which produce 
collagen and elastin – the main element of the connective tissue. The dermis is 
structurally divided into two areas: the Stratum papillare – a layer adjacent to 
the epidermis - and a deeper area called Stratum retuculare. The Stratum 
papillare is composed of loose areolar connective tissue. The Stratum retuculare 
is composed of dense irregular connective tissue.  
The hypodermis is not a part of the skin and is located below the dermis. It 
consists of loose connective tissue and elastin. The main cell types are 
fibroblasts, macrophages and adipocytes.          
 
2.2.2  Drug permeation through the skin 
Drugs which are applied onto the skin can be intended for local or systemic 
therapy. When the drug permeates through skin and reaches the systemic 
circulation, systemic effects as well as side effects are caused. The SC is a main 
barrier for drug penetration and absorption during topical drug administration. 
The drugs can penetrate through different pathways such as passive diffusion 
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along the transcellular route (through corneocytes) or along the concentration 
gradient by the intercellular route. Moreover, the glandular and transfollicular 
routes play a role in drug penetration (Ritschel and Hussain, 1988). Important 
factors which influence the way of the drug penetration are: 
- molecule size,  
- chemical structure of the molecule,  
- molecule polarity,  
- partition coefficient between the phases,  
- hydratation grade of the SC,  
- composition of the topical vehicle and  
- drug concentration (Niedner and Ziegenmeyer, 1992; Franz et al., 2003). 
The partition coefficient influences the drug release from the vehicle. Inverse 
proportionality between the drug release rate from the vehicle and vehicle 
lipophilicity was shown (Murakami et al., 1998). Polar drugs penetrate along the 
transcellular pathway; drugs with low polarity use the intercellular pathway. 
After release from the vehicle, diffusion to the skin surface and penetration 
through the SC, the drug permeates through the living cell layer und can reach 
the blood vessels in the dermis, where a systemic absorption and the transport 
can take place. Nevertheless, the drug penetration rate through the SC is a main 
factor which defines the velocity of drug absorption. Systemic effects of the 
topically applicable drug are dependent on its permeation rate. Penetration 
enhancers can act through different mechanisms to increase the penetration rate. 
The SC can also be a reservoir for topical drugs (Roberts et at., 2004). The drug 
penetration rate is, therefore, also dependent on its reservoir capacity (Rougier et 
al., 1983). 
In permeation studies, skin tissue is oversimplified to an isotropic membrane, 
through which a passive diffusion of the dissolved drug takes place.  
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The driving force of this process is a concentration gradient which defines the 
diffusion rate. The drug permeation profile can be defined through plotting the 
cumulative penetrated drug amount per area at a defined time point against the 
time.  
For investigation of the drug reservoir capacity of the SC, the tape-stripping 
technique can be used. Single layers of the SC are taken away by skin biopsy 
which is carried out with an adhesive tape. The drug is than extracted and 
analytically assayed (Wiechers et al., 1989). 
Animal skin models (domestic pig skin, rodent guinea pig skin, rat skin) can be 
used for these studies as well. Pig ear skin is not completely physiologically and 
histologically equivalent to human skin, nevertheless, it was shown to be an in 
vitro tool for investigation of drug permeation through the skin (Dick and Scott, 
1992; Sekkat et al., 2002; Jacobi et al., 2007; Vallet et al., 2007; Barbero and 
Frasch, 2009). Pig ear skin disposes only few hair follicles and the follicular 
pathway in this case can be neglected.  
Human skin for the permeation studies can be obtained as a waste product after 
plastic surgery.  
Reconstructed human skin equivalents e.g. EpiDerm® can be also employed. It 
consists of normal, human-derived epidermal keratinocytes and is cultivated on 
microporous membranes (Wagner et al., 2001; Lotte et al., 2002). 
               
2.3 Topical diseases affecting the scalp region 
Topical diseases with scalp involvement require a treatment adapted to the 
particularities of this anatomical site. Social effects are connected with 
pathological scalp conditions. Therapeutic complexity, on the other hand, 
contributes to the psychological distress (Zschocke et al., 2005).  
Application of topical corticosteroids is the most frequently used treatment 
option (van der Kerkhof et al., 1999). The vehicle itself plays a significant role 
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in the treatment of the scalp area. The choice of the vehicle depends on its 
cosmetic aspect. Ideally, easy-to-use vehicles are preferred since they improve 
the compliance to therapy (Wauters et al., 2007). Patient’s compliance is 
reported to be better for liquid or foam formulations than for creams and lotions 
(Feldman and Housman, 2003; Uhoda et al., 2004). 
 
2.3.1  Scalp psoriasis 
Psoriasis is a chronic, inflammatory and hyperproliferative skin disease with a 
genetic basis. Multiple environmental factors are also afflicted to the 
pathogenesis of psoriasis. Psoriasis is characterized by distinct increased 
proliferation and incomplete differentiation of the epidermis, a marked increase 
in cutaneous blood flow and leukocytic infiltration of the papillary dermis and 
epidermis. However, the molecular reactions triggering this state of 
immunologic activation remain unclear (Gudjonsson and Elder, 2007).  
Scalp is a well-known predilection site for psoriasis. The affected skin areas, 
called plaques or lesions, are inflamed or covered with silvery white scales 
which appear particularly along the hair line (Naldi and Gambini, 2007). Scalp 
psoriasis is limited to the scalp alone or can be associated with type I and type II 
psoriasis, pustular psoriasis, erythrodermia and psoriatic arthritis (Wozel, 2008). 
Many patients indicate that scalp psoriasis is both psychologically and socially 
distressing and the most difficult aspect of their disease. Itch and scaling are 
reported to be the leading symptoms in terms of frequency of occurrence as well 
as in terms of distress (van der Kerkhof et al., 1999; Papp et al., 2007). 
The erythematosquamous lesions on the scalp are mostly asymmetrical, sharply 
demarcated, showing a silver-white scaling and pruritus. 
It was shown that responses of T-cells are abnormal in this disease. Abnormally 
activated T-cells elaborate cytokines inappropriately, perpetuating inflammation 
which, in turn, leads to skin damage manifesting clinically as psoriasis.  
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Tumor necrosis factor (TNF-α), produced by keratinocytes, activated T-cells, 
macrophages and dendritic cells plays a central role in the pathogenesis of 
psoriasis. TNF-α stimulates and propagates widespread immunological activity 
by targeting various cells in the skin, such as endothelial cells, keratinocytes and 
dendritic cells (Chong and Wong, 2007). TNF-α induces keratinocytes to 
express at least 70 genes, ranging from chemokines to other cytokines. In 
addition, under the influence of TNF-α, macrophages generate cytokines and 
chemokines and dendritic cells undergo maturation in preparation to present 
antigens to T-cells.  
The main therapeutic classes of current standard treatment of scalp psoriasis are 
dermocorticosteroids, keratolytics e.g. salicylic acid 5% to 10%, antimycotics, 
vitamin A derivatives e.g. tazarotene and vitamin D derivatives e.g. calcipotriol 
for topical application (Gottlieb, 2005; Bos and Spuls, 2008). A topical 
combination of corticosteroid and vitamin D derivative appears to provide a 
balanced approach to psoriasis treatment (Del Rosso, 2006). Coal tar shampoos, 
containing 2% to 10% coal tar solution are also effective in scalp psoriasis. 
Dithranol 0.1% to 3% can be also used. The management of scalp psoriasis 
requires long term strategies in order to reach an optimal improvement of the 
symptoms while avoiding adverse effects associated with long term use of 
medicaments. The main aim of the treatment is to reduce the burden of disease 
over time by controlling symptoms, helping the patient to cope with the chronic 
nature of the disease, limiting psychological consequences and preventing 
systemic complications (Naldi and Gambini, 2007).  
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2.3.2  Seborrheic dermatitis 
The term sebopsoriasis or seborrhiasis describes an overlap with psoriasis. In 
this condition, psoriasis mostly predominates, with associated facial 
involvement showing a greasy scaling with yellowish colour (Wozel, 2008). 
Common manifestations include erythema and variable pruritus (High et al., 
2006). Sites of predilection include areas rich in sebaceous follicles: the face, 
ears, neck, upper trunk, creases of the legs, arms and groin and the scalp. 
Dandruff, which affects 5% to 10% of the population, is considered to be the 
mildest or perhaps initial form of seborrheic dermatitis (Gupta et al., 2003). The 
origin of seborrheic dermatitis (SD) remains a matter of debate; e.g. the 
increased sebum production and the overgrowth of the scalp with Malassezia 
species is a well known feature of this disease (Naldi and Rebora, 2009). There 
is an increased incidence of SD in HIV and AIDS patients, suggesting that the 
immune system plays a role in the disease (Gupta et al., 2003). SD is associated 
with depression of T-cells, increased sebum levels and activation of the 
alternative complement pathway. 
There is an idea that not an absolute increase in sebum production but an 
increase of the static pool of already secreted sebum due to immobility and 
muscular paralysis plays a permissive role for growth of Malassezia yeasts and 
SD development. It was noted that in patients with neurologic disorders, such as 
Parkinson’s disease, multiple sclerosis and depression, an increased incidence of 
SD happens (Mastrolonardo et al., 2003). 
The treatment involves antifungal agents e.g. imidazole derivatives, often in 
combination with shampoos containing selenium sulphide or zinc pyrithione, but 
topical corticosteroids are commonly used for the treatment (van de Kerkhof and 
Franssen, 2001; Gupta et al., 2003; High et al., 2006). 
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2.3.3  Topical corticosteroids for the treatment of scalp diseases 
Corticosteroids for topical application are the first choice medicaments for 
treatment of scalp psoriasis (Chan et al., 2009). Topical corticosteroids were 
also shown to provide clinical benefits for the treatment of seborrheic dermatitis 
of the scalp (Shin et al., 2009). Corticosteroid therapy aims at strong anti-
inflammatory and antiproliferatory action. Topical corticosteroids are 
categorized by numerous classification systems based on different 
measurements, e.g. vasoconstrictor assay, UV-B-induced erythema test, 
psoriasis plaque test, atrophogenicity potential, (Del Rosso and Friedlander, 
2005). 
Corticosteroids are lipophilic substances and penetrate via the intercellular 
pathway. A strong reservoir effect for corticosteroids takes place in the SC. 
Depending on the intensity of the skin inflammation state it can last from 15 min 
to two hours for corticosteroids to penetrate through the SC. The living 
epidermis is permeated within a shorter period of time. Ointments, creams, 
lotions are conventional vehicles for topical delivery of corticosteroids. 
Corticosteroids for topical administration are different in the strength of their 
anti-inflammatory and antiproliferatory activity. Topical corticosteroids that are 
used nowadays, are drugs of the 4th generation. Because of their high anti-
inflammatory activity and low atrophogenic activity, they have an advanced 
benefit / risk ratio for the therapy of skin diseases (Wozel, 2008).  
The anti-inflammatory effect is connected with inhibition of phospholipase A-2 
and, therefore, inhibition of arachidonic acid synthesis as a prestage for 
prostaglandin synthesis. Antiproliferatory activity is due to simulation of RNA-
synthesis for special proteins which influence the glucose and aminoacids 
transport into cells (Hornstein and Nuernberg, 1985). 
The prevalent side effect of corticosteroids for topical application is a decrease 
of the epidermis and dermis thickness as the corticosteroids inhibit the apoptosis 
of keratinocytes. The degree of this skin atrophy is dependent on the activity of 
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corticosteroid, structure of the medicated area and duration of the treatment. 
Skin atrophy is rarely observed in the scalp, possibly because of its dense 
vascularization (Chan et al., 2009). Corticosteroids inhibit the division of 
keratinocytes and also show antiproliferatory activity for fibroblasts. Protein 
synthesis of fibroblasts is inhibited as well. Interleukin IL-1α is involved to 
inflammation within keratinocytes. Within fibroblasts, IL-1α and IL-6 are 
involved into cell proliferation. Therefore, effective inhibition of interleukin 
synthesis within keratinocytes leads to an anti-inflammatory effect, but within 
fibroblasts, in contrast, to an antiproliferatory effect. Hindered proliferatory 
activity leads to reduction of the dermis and epidermis thickness. Skin becomes 
thinner and less elastic. The chemotaxis activity of fibroblasts is also reduced, 
which can lead to dysfunction of the wound healing process. Corticosteroids 
also decrease synthesis of collagen and mucopolysaccharides in the dermis, by 
reduction of the procollagen gene expression (Del Rosso and Friedlander, 2005). 
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3 Materials and Methods 
3.1 Materials 
3.1.1  Foaming agents 
Different surfactants from different chemical groups (Table 2) were tested, 
initially, to define their activity as foaming agents. The ability of these 
surfactants to generate a foam and foam stability characteristics were 
investigated by means of a foamability method after Jellinek (1959), (see 
3.2.1.1). Secondly, the surfactants should have an ability to solubilize a 
lipophilic active component in emulsion-based foamable formulations. Based on 
the preliminary test, a foaming agent or a foaming agents’ combination and a 
solubilizing agent or solubilizing agents’ combination were chosen for further 
formulation development. Moreover, the surface activity of foaming agents as 
well as the critical micelle concentration was measured by means of the 
Wilhelmy plate method. 
 
3.1.2  W/O surfactants 
Following w/o surfactants were used for formulation development (Table 3). All 
used w/o surfactants were nonionic with exception of Lanette® O, which was 
anionic. 
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Table 2 Foaming agents 
Trade name 
 
Chemical name Group Supplied by 
Medialan® Sodium lauryl sarcoside, 30% 
solution 
Anionic Clariant GmbH,Germany 
Hostapon® Sodium cocoyl glutamate 
 
Anionic Clariant GmbH,Germany 
Serwet® WH 172 Sodium di-2-ethylhexyl 
sulfosuccinate  
60% solution in  
1,2-propylenglycol/ water 
Anionic Condea Servo,Germany 
 
Rewopol® SB CS 50K Disodium polyoxyethylene-5 
lauryl citrate sulfosuccinate; 
sodium laureth sulfate  
Anionic Degussa/Goldschmidt  
GmbH, Germany 
Texapon® K 12 Sodium lauryl sulfate 
 
Anionic Caesar & Loretz GmbH, Germany 
TEGO Betain® L7  Cocamidopropyl betain 
 
Amphoteric Degussa/Goldschmidt GmbH, 
Germany 
TEGO Betain® 810 Capryl/capramidopropyl betain Amphoteric Degussa/Goldschmidt  
GmbH, Germany 
TEGO Care® CG90 Cetyl stearyl glucoside Nonionic Degussa/Goldschmidt  
GmbH, Germany 
Plantaren®818 UP Coco glucoside 
 
Nonionic Cognis Care, Germany 
- Sucrose laurate 
 
Nonionic Harke Group, Germany 
Imwitor® 380 Citric/lactic acid ester of partial 
glycerides 
Nonionic Nordmann, Rassmann 
GmbH, Germany 
ABIL® Care 85 Bis- polyoxyethylene/ 
polyoxypropylene 16/16 
polyoxyethylene/ 
polyoxypropylene 16/16 
dimethicone; 
caprylic/capric triglyceride  
Nonionic Degussa/Goldschmidt  
GmbH, Germany 
Teginacid®C Polyoxyethylene (25) 
cethyl stearyl ether 
Nonionic EVONIK/Goldschmidt  
GmbH, Germany 
Eumulgin®B2 Polyoxyethylene (20) 
cethyl stearyl ether 
Nonionic Cognis Care, Germany 
TAGAT®CH 40 Polyoxyethylene (40) ricinoleate Nonionic Caesar & Loretz GmbH, Germany 
TAGAT® S2 Polyoxyethylene (20) 
glyceryl monostearate 
Nonionic Caesar & Loretz GmbH, Germany 
TAGAT® 02 Polyoxyethylene (20) 
glyceryl monooleate 
Nonionic Caesar & Loretz GmbH, Germany 
TAGAT® L2 Polyoxyethylene (20) 
glyceryl monolaurate 
Nonionic Caesar & Loretz GmbH, Germany 
TEGO® SML Sorbitan monolaurate 
 
Nonionic Caesar & Loretz GmbH, Germany 
Brij® 35 Polyoxyethylene (23) lauryl ether Nonionic FLUKA Chemie AG, Germany 
Brij® 58 Polyoxyethylene (20) cetyl ether  Nonionic FLUKA Chemie AG, Germany 
Brij® 98 Polyoxyethylene (20) oleyl ether Nonionic FLUKA Chemie AG, Germany 
Tween® 20 Polyoxyethylene (20) sorbitan 
monolaurate 
Nonionic Caesar & Loretz GmbH, Germany 
Tween® 40 Polyoxyethylene (20) sorbitan 
monopalmitate 
Nonionic Caesar & Loretz GmbH, Germany 
Tween® 60 Polyoxyethylene (20) sorbitan 
monostearate 
Nonionic Caesar & Loretz GmbH, Germany 
Tween® 80 Polyoxyethylene (20) sorbitan 
monooleate 
Nonionic Caesar & Loretz GmbH, Germany 
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Table 3 W/O surfactants 
Trade 
name 
HLB value Chemical name Supplied by 
Brij® 72 4.9 Polyoxyethylene (2) 
stearyl ether 
I. C. I. Surfactants, Belgium
Span® 20 8.6 Sorbitane monolaurate Croda Iberica SA, Spain 
 
Span® 80
  
4.3 Sorbitane monooleate Croda Iberica SA, Spain 
 
Lanette® O 1.5 Cetyl stearyl alcohol Caesar & Loretz GmbH, 
Germany 
 
3.1.3  Foam stabilizing agents 
In preliminary tests, gelling agents and their combinations were used in different 
concentrations to increase foam stability for determination of the optimal 
stabilizing agent. An increase of foam stability in this case is due to the increase 
of solution bulk viscosity and, therefore, slowing down the process of foam 
drainage. Surface activity of foam stabilizing agents was measured by means of 
the Wihelmy plate method. 
 
3.1.3.1 Cellulose derivatives 
The hydrophobic part of cellulose derivatives adsorbs at the oil-water interface. 
The hydrophilic part swells in water forming a gel network around the oil 
droplets providing on the one hand emulsion stability (Rimpler, 1996). On the 
other hand through increase of formulation viscosity, the foam liquid drainage is 
slowed down and stabilization is reached. Both effects were utilized in the 
formulation studies. 
The viscosity of cellulose derivatives’ colloidal solutions is dependent on the 
length of the polymer chain and the polymer concentration. Solutions with 
higher polymer concentration show a pseudoplastic flow behavior. But at low 
concentrations, deviation from the Newtonian flow can be neglected.  
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Therefore, determination of solution complex viscosity at low concentrations 
can be carried out as one-point measurement. These measurements were 
performed by means of oscillatory rheology (see 3.2.1.2). Surface tension of the 
solutions was determined using the Wilhelmy plate method. Methyl cellulose 
(MC, Tylose MH 300, Hoechst AG, Germany) and hydroxypropyl methyl 
cellulose (HPMC, Metolose 60 SH 50, Shin-Etsu Chemical Co. Ltd, Japan) were 
used for these studies (Figure 4).  
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Figure 4 General structure of cellulose derivatives  
 
3.1.3.2 Xanthan gum 
Xanthan gum (Xanthan Gum Powder 200 Mesh, Alfred L. Wolff GmbH, 
Germany) is a high molecular weight polysaccharide with a backbone made up 
of β-1,4-linked D-glucose molecules (Figure 5). A trisaccharide branch 
containing one glucuronic acid unit between two mannose units is linked to 
every other glucose unit at position 3. Xanthan gum is able to produce a large 
increase of viscosity at a concentration as low as 0.5%. The colloidal solutions 
of xanthan gum have a pseudoplastic flow behavior. At low concentrations, 
nevertheless, the pseudoplasticity can be neglected, allowing one point 
measurements of viscosity (Alfred L. Wolff GmbH, User information of 
product). 
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Figure 5 Structure of xanthan gum 
 
3.1.3.3 Polymers of polyacrylic acid 
3.1.3.3.1 Carbopol® 
Carbopol® (981 PNF, Noveon Inc., USA) polymers are acrylic acid polymers 
with high molecular weight. These polymers are used as a gelling agent. For 
viscosity increase, neutralization, i. e. converting the free carboxyl groups to the 
salt form, is essential. In the range of pH 3-6 a considerable increase of viscosity 
happens which remains constant to pH 10 and then decreases. 
 
3.1.3.3.2 Pemulen® 
Pemulen® (TR-2 NF, Noveon Inc., USA) polymers are high molecular weight 
polymers of acrylic acid modified by long chain (C10-C30) alkyl acrylates and 
crosslinked with allylpenthaerythritol, containing both hydrophilic and 
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hydrophobic parts within the molecule. They are primarily used to form stable 
oil-in-water emulsions. The proposed mechanism of emulsion stabilization by 
these emulsifiers is named electrosteric stabilization and represents a combined 
effect of electric repulsion and steric stabilization. In the presence of an oil 
phase, hydrophobic alkyl chains anchor to the surface of oil droplets by 
hydrophobic interactions. At the same time, the long hydrated and negatively 
charged hydrophilic chains form microgels around dispersed oil droplets and, 
therefore, prevent their coalescence (Simovic et al., 1999). In formulation 
studies this excipient was used as foam stabilizing agent and emulsion 
stabilizing agent. The increase of viscosity happens under neutralization in the 
range of pH value 4 to 10 with the maximum at pH values 5 to 7. 
 
3.1.4  Solvents 
Different solvents (Table 4) were used to dissolve the model drug for the 
development of low viscous solution-based foamable formulations for foam 
generation by means of the Airspray® foam dispenser. 
 
Table 4 Solvents 
Trade name Chemical name Supplied by 
- Propylene glycol Caesar & Loretz GmbH, German 
- Hexylene glycol Caesar & Loretz GmbH, Germany 
Pharmasolve® N-methyl-2-pyrrolidone ISP Technologies, Inc., UK 
Arlasolve® Dimethyl isosorbide ICI Surfactants, Belgium 
 
3.1.5  Oil phase 
Different oils (Table 5) were used in the formulation studies to develop a low 
viscous foamable emulsion for foam generation by means of the Airspray® foam 
dispenser.  
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Table 5 Oil phase 
Oil Chemical group Density1, 
g·cm-3 
Supplied by 
Medium chain 
triglycerides 
Ttriglyceride 0.95-0.96 Sasol GmbH, Germany 
Olive oil Triglyceride 0.92 Caesar & Loretz GmbH, 
Germany 
Soybean oil Triglyceride 0.92-0.93 Caesar & Loretz GmbH, 
Germany 
Paraffin oil 
 
Hydrocarbone 0.83-0.87 MKR & Co. Ltd, UK 
Abil 100 Silicone oil 0.93-0.97 Goldschmidt  
GmbH, Germany 
Cyclomethicone 
 
Silicone oil - Dow Corning, Belgium 
Isopropyl palpitate 
 
Wax 0.85 Cognis Care, Germany 
Isopropyl myristate 
 
Wax 0.86 Cognis Care, Germany 
Oleyl oleate 
 
Wax - Cognis Care, Germany 
1- literature data 
 
3.1.6  Betamethasone-17-valerate 
Betamethasone-17-valerate (BMV, Synopharm GmbH, Germany) is a lipophilic 
(logP 3.98) corticosteroid. Its high activity is caused by the F-atom in 9α 
position (Figure 6). At basic pH values an isomerisation to betamethasone-21-
valerate (BM21V) can take place. The 21-ester is less active than the 17-ester; it 
has approximately 15% of the biologic activity of the 17-ester. The 21-ester is 
metabolized through an esterase to betamethasone which is not active by topical 
application. The 17-ester is on the other hand stable to the activity of the 
cutaneous esterase which is responsible for cutaneous metabolism. This is the 
reason for entrapping of corticosteroid molecules within several days in SC 
(reservoir effect). The stability optimum for the formulation is at pH 4.5.  
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Figure 6 Structure of betamethasone-17-valerate 
 
3.1.7  Buffer solution 
Phosphate buffer solution pH 4.5 (Ph. Eur. 6.0) was used for maintaining the pH 
optimum for BMV.   
 
3.1.8  Preservative  
Sodium benzoate 0.1% was used as a preservative for the BMV formulations. 
 
3.1.9  Airspray® foam dispenser 
The Airspray® Pump foam dispenser (Airspray International, Netherlands) was 
used for propellant free foam generation. The main parts of the dispenser are a 
liquid reservoir, air and liquid dosing chambers, a piston with bore holes and 
diaphragm valve, a foam generator with a double sieve and a foam generation 
head (Figure 7). 
The foam quality generated by Airspray® foam dispensers differs from that 
generated by means of a propellant (aerosol foam). Aerosol foams are finer 
pored and more viscous than those generated in a propellant-free way (Figure 8).  
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Steel spring 
with ball valve
Air dosing chamber
Piston with bore holes and
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Seal
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Figure 7  Illustration of the Airspray® foam dispenser 
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Figure 8 Microscopic and macroscopic comparison    
  A. Aerosol foam 
  B. Airspray® foam 
 
3.1.9.1 Principle of foam generation 
Principle of foam generation by means of Airspray® foam dispenser is presented 
in Figure 9.  
In the stationary position the liquid dosing chamber (a) is filled with the 
formulation. The ball valve (b) of the chamber is closed and the steel spring (c) 
is released. In the operating position, the air in the air dosing chamber is 
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compressed by a piston (d). At the same time the bore holes of the piston in the 
air dosing chamber are closed by a diaphragm valve (e). The steel spring is 
compressed and the ball valve of the liquid dosing chamber is closed. The 
formulation from the formulation dosing chamber and air from the air dosing 
chamber are transferred through an uptake tube (f) and pressed through a foam 
generator with a double sieve (g). In the discharge position the compressed steel 
spring moves the piston of the air dosing chamber in the stationary position. The 
diaphragm valve of the air dosing chamber opens and lets the chamber to be 
filled with air. The ball valve of the liquid dosing chamber opens and the empty 
dosing chamber can be filled with formulation.  
 
Double sieve
for foam generation
Air dosing chamber
Liquid dosing 
chamber
Foam
Double sieve
for foam generation
Double sieve
for foam generation
 Air dosing chamber
Liquid dosing 
chamber
 Air dosing chamber
Liquid dosing 
chamber
a a
a b
bb
c
c
c
d
d
d
e
e
e
f
f
f
g
g
g
Stationary position Operating position Discharge position  
Figure 9 Mechanism of foam generation by the Airspray® foam dispenser 
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3.1.10 Pressurized aerosol foams 
Emulsion- and solution-based foamable formulations were used further for 
aerosol foam generation. The formulations were filled into aerosol packages 
which comprise a glass container, valve and an actuator.  
 
3.1.10.1 Containers, valves, actuators 
Glass containers (aerosol dome 15 mL, glass type III, transparent, Saint-Gobain-
Glass AG, Germany) were used to observe instability processes in formulations. 
Foam valves without a metering chamber were used for foam generation (KCO 
20 mm valves, Lindal Group, Germany). The valves comprise a stem made of 
polyethylene and a valve seat made of anodized silver aluminum. The valve seal 
(Buna 168S) is compatible with solvents, surface active substances and 
propellant used in the formulation. The foam actuator was fixed to the valve to 
dispense the aerosol foam (251/321 white foam actuator, Valois, Germany), (see 
Figure 2).  
 
3.1.10.2 Propellant mix 
An isobutane : n-butane : propane blend (14.83 mol/% : 29.75 mol/% : 55.42 
mol/% respectively, Air Liquide GmbH, Germany) at a concentration of 8 % 
(m/m) was used as a propellant. Application of such propellant amount is 
described in literature (Voigt, 2006).   
 
3.1.10.3 Propellant filling process 
An aerosol container was filled with formulation and a foam valve was crimped 
onto the aerosol container. The propellant filling process was carried out through 
the valve at the Pamasol filling and sealing machine (type 2016, Pamasol Willi 
Mäder AG, Switzerland). Filling control was carried out gravimetrically. 
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3.2 Methods 
3.2.1  Preliminary methods 
Preliminary methods were used as screening methods to choose the foaming 
agents, foam stabilizing agents, oils for formulation studies of emulsion-based 
foamable formulations and solvents for formulation studies of solution-based 
foamable formulations. 
 
3.2.1.1 Foamability and foam stability screening test for foaming 
agents 
A modified test after Jellinek (1959) was performed. Solutions of different 
surfactants in water were prepared in concentrations of 1%, 2%, 3%, 4% and 
5%. One mL of each solution was placed in a small graduated container. The 
solutions were shaken by hand for one minute and the height of the foam 
column was determined by means of a graduated scale. The stability of the 
generated foams was determined as a height of the foam column after 15 min 
and 30 min after foam generation. Tests were carried out at room temperature 
(25°C). 
 
3.2.1.2 Oscillation rheometry 
The determination of the viscoelastic properties of macromolecules was carried 
out by means of a Bohlin rheometer (Bohlin rheometer CVO 120 HR, Bohlin 
Instruments GmbH, Germany). The plate-plate measuring modus (plate diameter 
40 mm) with automatic gap size adjustment (50 µm) was used. The temperature 
of the plates was maintained at 25°C. The oscillation measurements were carried 
out at constant shear stress which was determined within the linear visco-elastic 
interval. This linear visco-elastic interval was determined via performance of an 
amplitude sweep (frequency 1 Hz, 20 measurement points) before each 
measurement. The dependent variable of the oscillation measurements is the 
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complex viscosity η* (Pa·s). The complex viscosity corresponds to the dynamic 
viscosity and can be divided into elastic and viscous parts. Determination of the 
complex viscosity was carried out through a 10 point measurement (Schramm, 
1995). 
 
3.2.1.3 Measurements of surface tension and determination of critical 
micelle concentration  
Critical micelle concentration (CMC) is the saturation point of a surface active 
substance in a water system. It is defined as the point where the surfactant 
molecules in solution are in equilibrium with the surfactant molecules in the 
air/water interface. At this point no changes in the surface tension are detectable 
upon further increase of the surfactant concentration. 
The determination of surface tension and critical micelle concentration was 
carried out with a Processor tensiometer K12 using K122 software (KRÜSS 
GmbH, Hamburg, Germany). The Processor tensiometer was connected with a 
thermostated water bath to control the temperature (25°C ± 1°C). 
The ring method (DuNouy ring) which is based on force measurements, was 
used. The ring is submerged below the solution interface (dipping distance 2.00 
mm) and raised upwards. As the ring is brought upwards, it raises a lamella of 
liquid and the measured force starts to increase. The maximum force is reached 
when the lamella tears from the ring. The measurements were carried out with a 
10.00 sec interval and done in triplicate. Before each measurement the ring was 
rinsed with demineralized water, annealed with a Bunsen burner and cooled to 
room temperature. The sample vessel was rinsed several times with 
demineralized water and the sample solution. The tensiometer was calibrated 
with demineralized water until the value of 72 mN·m-1 was reached. 
For the determination of critical micelle concentration a series of solutions of 
different concentrations (w/v) was prepared. 
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3.2.1.4 Polarity measurements 
Oils differ from each other in their polarity which is relatively difficult to 
determine. The oil polarity was determined through measurements of the 
interfacial tension between the oil phase and water phase. The oil is, thus, more 
polar if the interfacial tension between this oil and the water phase is lower. It 
was decided arbitrarily for simplification sake to describe the oils with 
interfacial tension to water lower than 25 mN·m-1 as polar. Oils with interfacial 
tension to water higher than 25 mN·m-1 were described as nonpolar. The 
interfacial tension between the oil and water phase was measured with the 
Processor tensiometer K12. The ring method was used. The ring was brought 
below the surface of the oil phase and the oil phase was covered with the water 
phase (thickness of the water phase approximately 1 cm). As the ring was pulled 
out from the oil phase into the water phase the increase of the force was 
measured. Measurements were carried out in triplicate at 25°C.  
   
3.2.1.5 Solubility of BMV in different media 
Two methods were used for the determination of the BMV solubility in different 
media.  
HPLC method: BMV was added in excess to the stirred medium (magnetic 
stirrer / heater IKA Combimag RET, Germany) until the visual saturation point 
was detected as presence of a sediment on the bottom of the vessel. In case of 
semisolid media, the temperature was increased to bring the medium to its 
melting point to be able to stir it. Temperature influence on the solubility was 
neglected for the semi-solid components. The suspensions were stirred for 24 
hours and than centrifuged 15 min at 40°C and 20000 min-1 rotation speed 
(Heraeus Sepatech GmbH, Germany) to separate the sediment from the 
overlaying solution. The solution of the BMV was mixed with 2 mL of organic 
solvent (75% methanol : 25% water, v/v) to extract the BMV from the medium. 
The BMV amount was determined by means of HPLC (see Appendix).     
3 Materials and Methods 
 65
Visual determination: 
The solvent was added to a defined mass of BMV until no visual sediment was 
detected. The concentration of BMV in the medium was calculated. 
 
3.2.1.6 Determination of particle size / micelle size 
Particle size measurements were carried out by means of photon correlation 
spectroscopy (PCS, Zetasizer DTS Nano, Malvern Instruments Ltd, UK) with an 
automatic function for determination of measuring points per run (based on the 
signal strength and signal variation the program chooses the number of 
measuring points per single measurement, measurement duration 20 s). 
Measurements were carried out in triplicate approximately 24 h after preparation 
(storage at room temperature). Measurements were performed at 25°C and at a 
scattering angle of 173° at the wavelength of 633 nm. Only measurements with 
polydispersity index ≤ 0.7 were evaluated. The mean value and the standard 
deviation were calculated from three measurements (User guide, Zetasizer DTS 
Nano, Malvern Instruments Ltd).  
 
3.2.1.7 Determination of interfacial surfactant adsorption (velocity) 
Velocity of interfacial occupation by molecules of foaming agents was measured 
by means of the Contact Angle System OCA 20 (Dataphysics Instruments 
GmbH, Germany). The relaxing drop method was used. A water droplet was 
generated with a fine needle of 0.9 mm diameter (droplet volume range between 
10 and 19 µl). Surface tension was measured and assured to be 72 mN·m-1. 
Surface tension was calculated from the shape of generated droplet. 1.0% 
solution of foaming agent was dosed to this droplet with a second needle of 
smaller diameter (0.5-2.0 µl). This measuring facility was constructed in-house 
(Department of Food Technology, Christian Albrecht University, Kiel, 
Germany). During the dosing and after dosing, surface tension was observed 
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over the next minute. Single measurements of surface tension and droplet 
volume were performed each second, so that at the end of measurement time 
approximately 60 to 80 single measurement points were determined. 
Measurements were carried out at room temperature.  
     
3.2.2 General methods 
3.2.2.1 Foam characterization 
3.2.2.1.1 Cylinder method (Detection of foamability and foam stability) 
Foam stability is usually reflected by the initial foam volume and subsequent 
measurements of the volume as a foam ages.  
A cylinder test was carried out to determine the following parameters: foam 
expansion (FE, %, Equation 6), foam liquid stability (FLS, %, Equation 7) and 
foam volume stability (FVS, %, Equation 8). Foam gas fraction was determined 
as the difference between the initial foam volume and volume of the 
nonexpanded formulation (Equation 9). 
( ) %100
)(
)()(% ⋅−=
nformulatioV
nformulatioVfoamVFE      Equation 6 
)( foamV - volume of produced foam, ( )mL  
)( nformulatioV - volume of formulation to produce )( foamV , ( )mL  
 
%100
)(
(
(%) min)30 ⋅=
nformulatioV
liquidV
FLS        Equation 7 
( )min30liquidV - volume of liquid drained after 30 min 
 
( ) %100
)(
(%) min30 ⋅=
foamV
foamVFVS        Equation 8 
( )min30foamV - volume of foam after 30 min 
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)()()( nformulatioVfoamVmLGF −=       Equation 9 
)( foamV - initial foam volume 
)( nformulatioV  - volume of nonexpanded formulation 
The higher the FE the more foamable is the formulation. The lower the FLS and 
the higher the FVS the more stable is the produced foam.  
The foam was discharged into a glass cylinder. The initial volume of foam, the 
volume of the aged foam and the volume of drained liquid after a defined time 
period was measured (Figure 10). The separation of the liquid due to liquid 
drainage was observed after 15 min. 
 
A. B.
 
Figure 10  Cylinder method 
   A. Foam volume direct after foam generation 
B. Decreased foam volume with drained liquid after 15 min 
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3.2.2.1.2 Foam texture (Texture Analyser) 
Properties which principally influence foam firmness are surface viscosity, bulk 
liquid viscosity, bubble size distribution and foam geometry. Therefore, 
generated foams were characterized using a customized, newly developed 
method with a Texture Analyser (TA, Texture Analyser TA.XT.plus, Stable 
Micro Systems, UK). The instrument is equipped with a load cell registering the 
mass acting on it. Although not completely correct, the measured mass is 
displayed as force in (g) from the instrument which can easily be transformed 
into the gravitational force Fg (N) by multiplication with the gravitational 
acceleration of 9.80665 m·s-2. To simplify matters, the instrument output 
’’force’’ in (g) was used for the evaluation of the results. The foam was 
dispensed into a container and then stressed with a disk (diameter 45 mm) which 
was pressed through the foam to a specified depth (10 mm). Test speed was 
preset to 0.5 mm·s-1 and control force to 1.0 g. Measurements were carried out in 
triplicate. From the resultant force-time curve, the required forces were 
recorded. During penetration the force gradually increases until the point of 
maximum penetration depth is reached. The sample then proceeds to withdraw 
from the disk. A force is required to overcome the foam stickiness. The 
maximum positive force indicates the firmness of the sample. The maximum 
negative force indicates the stickiness of the sample (Figure 11).  
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Figure 11 Force-time plot to measure foam firmness as derived from a Texture 
Analyser 
 
3.2.2.1.3 Light (back-) scattering method (Foam stability) 
Light (back-) scattering method is based on the Faraday-Tindall effect which 
postulates that colloidal solutions can scatter light. Differences in refractive 
indices between the solution of foaming agent and air result in different 
intensities of light transmission and light backscattering. Intensities of 
transmitted and backscattered light are dependent on the amount of air in foam. 
During the process of foam destabilization, the amount of air changes in 
different depths of the measuring cell as a result of air bubble growth (foam 
ripening) and liquid drainage. Therefore, transmission and backscattering signals 
also change.  
Because of different refractive indices of both phases, interactions of photons 
(diffusion and diffraction) happen. The backscattering signal (BS) is inversely 
proportional to the square root of the mean free distance covered by a photon 
being backscattered (Equation 10). 
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∗≈ lBS
1           Equation 10 
 
l*- mean free distance covered by a photon, ( )m  
The higher the phase volume of gas in the foam, the shorter is the free distance 
covered by a photon and, therefore, the more intense is backscattering and the 
less intensive is transmission. 
For the measurements, the foam was dispensed into a glass measuring cell and 
scanned through with infrared light (λ = 850 nm). A light source and two 
detectors move along the measuring cell and backscattering and transmission 
signals are detected every 40 µm from the bottom of the cell to the height of 
55 mm (Turbiscan LabExpert, Formulaction, l´Union, France). Therefore, such 
physical processes as liquid drainage at the bottom and air bubble growth in the 
bulk of the foam can be detected. Intensity of the backscattered light is detected 
under the angle of 45° (nephelometry). Intensity of the transmitted light is 
detected under the angle of 180° (turbidimetry). Under this angle only the 
photons that do not change their orientation are registered. Transmission and 
backscattering intensities are given as measurements results over the whole 
height of the measurement cell.  
A sample scan is shown exemplarily in Figure 12. A clear transmission signal 
can be detected at the bottom (approximately at the height of 15 mm) of the 
measurement cell (Figure 12, top). At this height, the light can be transmitted 
through a phase of separated (drained) liquid. This signal is also called a 
drainage peak.  
At the central part of the measurement cell (20-35 mm) no transmission signal 
can be observed. The light can not be transmitted because of the high 
concentration of dispersed air bubbles.  
3 Materials and Methods 
 71
During foam destabilization process the foam volume would decrease, therefore, 
at the upper part of the measurement cell (35-55 mm) the transmission signal 
can be observed again. This signal should only be treated as a shift of the foam 
meniscus and not as a development of a new phase. 
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Figure 12 A. Backscattering profiles from a Turbiscan analysis 
B. Transmission profiles 
 
When a transmission signal is detected, there will also be a backscattering signal 
at the same zone (Figure 12, bottom). This signal should not be evaluated, as the 
reason for this signal is a secondary light reflection at the wall of the 
measurement cell.  
Foam ripening in the bulk of the foam (central part of the measurement cell, 
20-35 mm) illustrates the growth of air bubbles in the foam and can be detected 
as a parallel shift of the backscattering intensity curve to lower values. 
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For foam sample analysis the change of transmission intensity is evaluated over 
time as a change in the thickness of the liquid drainage peak. A delta H (t) 
kinetic curve is obtained. The slope of this curve reproduces the development of 
the liquid phase in mm·min-1.  
Change of backscattering intensity is analyzed as a mean value kinetic curve or 
delta BS (t) curve at the central part of the measurement cell. Interference 
factors, such as negative backscattering peaks at the bottom or the shift of the 
foam meniscus at the top, should be avoided. The slope of this curve represents 
the increase of air bubble size over the time (%·min-1). 
These analyses are typically carried out in the reference-mode where all 
obtained curves are compared to the chosen initial curve. In this mode, changes 
in the intensities can be better estimated. 
In the non-reference mode it is possible to detect the initial and the final value 
for backscattering. The difference of these two values shows the change in air 
bubble size over measurement time.  
Samples were analyzed at 25°C. Foam stability was observed for 15 min. 
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3.2.2.2 Emulsion based foamable formulations 
3.2.2.2.1 Production of oil-in-water (o/w) emulsions 
To avoid pronounced foam generation leading to loss of foaming and 
emulsifying agent during production of oil-in-water emulsions, the production 
process was optimized according to the following process flow chart (Table 6). 
 
Table 6 Choice of production method / 1 
Method Oil phase Water phase Incorporation Foam generation 
1 Heated  
up to 55°C 
Foaming agent 
added, heated 
up to 55°C 
Water phase 
into the oil 
phase 
Intense foam 
generation 
 
2 Heated  
up to 55°C 
Foaming agent 
added, heated 
up to 55°C 
Oil phase into 
the water 
phase 
Intense foam 
generation 
 
3 Foaming 
agent 
added, 
heated up 
to 55°C 
Heated  
up to 55°C 
Water phase 
into the oil 
phase 
Intense foam 
generation 
 
4 Foaming 
agent 
added, 
heated up 
to 55°C 
Heated  
up to 55°C 
Oil phase into 
the water 
phase 
The intense foam 
generation is 
avoided 
 
Following the findings of this preliminary investigation the ´´hot-hot´´ emulsion 
inversion method (method number 4) was applied. The phase inversion 
temperature method is based on the changes in solubility of polyoxyethylene-
type nonionic surfactants with temperature. This type of surfactants becomes 
more lipophilic with increasing temperature because of dehydration of the 
polyothyethylene chains.  
The foaming agent or foaming agent composition (acting in this case also as 
emulsifiers for o/w emulsion) was dissolved in the dispersed phase (oil phase) 
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and the oil phase was heated up to 55°C (water bath, Polzin Laborbedarf, 
Germany). The continuous phase (aqueous phase) was separately heated up to 
55°C. The oil phase with dissolved foaming agent was gradually added to the 
water phase and dispersed with an ultra turrax (8000 rpm) for 5 min (T25 basic 
IKA Labortechnik, Germany). The formulation was cooled down at continuous 
stirring to room temperature for another 5 min. The duration of dispersion and 
the speed of the ultra turrax were also determined during preliminary 
investigations. The speed and duration, where no intense foam generation took 
place, were chosen (Table 7). When betamethasone-17-valerate was 
incorporated into the formulation, it was combined with the oil phase before 
phase merging.  
 
Table 7 Choice of production method / 2 
Time, min Speed, rpm Notes 
15 20500 Intense foam generation 
 
15 13500 Intense foam generation 
 
15 8000 Intense foam generation 
 
10 20500 Intense foam generation 
 
10 13500 Intense foam generation 
 
10 8000 Acceptable foam generation  
 
5 20500 Intense foam generation 
 
5 13500 Intense foam generation 
 
5 8000 Acceptable foam generation 
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3.2.2.2.2 Stability tests 
Oil-in-water emulsions should be stable at least two years through storage under 
normal conditions. To evaluate the stability of foaming formulations within a 
shorter time period, accelerated thermal and physical stress tests were employed. 
High temperature-low temperature cycles 
Samples were stored under accelerated thermal conditions in a thermostated 
cabinet (Rumed 3501, Rubarth Apparate GmbH, Germany). Temperature was 
changed from - 10°C to + 40°C within one cycle of 24 hours duration (Figure 
13). Samples were stored for 7 cycles, afterwards macroscopic evaluation of 
sample stability was carried out. Temperature change within one cycle was 
chosen to cover different storage conditions (Table 8). 
 
Table 8 Temperature program 
Temperature Condition 
- 10°C Cooled 
+8°C Refrigerated 
+25°C Room temperature 
+40°C Stress 
 
Centrifuge test 
Samples were centrifuged (Biofuge A, Heraeus Sepatech GmbH, Germany) by 
increasing revolution (RPM) at room temperature for predefined time intervals 
(Table 9). Stability of the samples was evaluated macroscopically after each 
step. 
After accelerated stability tests, formulations were observed macroscopically 
and evaluated according to the following scheme after Quack et al. (1975, 
Table 10). 
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Figure 13 Temperature cycle  
 
Table 9  Centrifuge test 
Step RPM Duration, min 
1 1000 10 
2 3000 10 
3 5000 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Materials and Methods 
 77
Table 10 Stability evaluation schema for o/w emulsions1 
Note Characteristic 
0 Complete breakup into oil and water phase 
 
1 Clear breakup 
Intense coalescence 
2 Clear breakup 
Slight coalescence 
3 Clear breakup 
Slight coalescence 
Definite layer at the bottom 
4 Homogeneous upper phase 
Definite layer at the bottom 
5 Clear stripline 
Definite layer at the bottom 
6 Slightly noticeable stripline 
No definite layer at the bottom 
7 Slightly noticeable stripline 
Nearly homogeneous emulsion 
8 No noticeable stripline 
Completely homogeneous, unaltered emulsion 
1- modified after Quack et al. 
 
3.2.2.3 BMV release (liberation) from topical formulations 
The construction scheme of a Franz cell which was used for release and 
permeation studies is shown in the Figure 14 (Franz cell, Crown Glass Company 
Inc., USA). The acceptor compartment has a volume of 8 mL and the contact 
area between the donor and acceptor compartments is 1.00 cm2. The acceptor 
compartment was kept at 32°C by circulating water through a water jacket. For 
in vitro drug release tests from topical formulations different membrane systems 
can be used among others e.g. the artificial membranes saturated with n-octanol 
or oils with low polarity (Hueckstaedt, 2005).  
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Tempering jacket
Magnetic stirrer
Tube for sampling
Acceptor compartment
Filter / 
Pig ear full thickness skin / 
Human epidermis
Donor compartment
 
 
Figure 14 Franz cell  
  
Untreated cellulose acetate membranes (Whatman International Ltd, England) 
with a pore size of 0.2 µm and membranes saturated with isopropyl myristate 
were used for the release studies. Phosphate buffer solution pH 4.5 (Ph. Eur. 6.0) 
with 25% (v/v) methanol was used as acceptor medium. It was ensured that 
perfect sink conditions were present (i.e. that the concentration of the drug in the 
acceptor medium was below 10% of the solubility of the drug in the medium).   
Artificial membranes were fixed between the compartments assuring that no air 
bubbles from the acceptor medium are trapped under the membrane. The 
formulations were applied onto the membrane (0.5 g) between the upper and 
lower chamber of the diffusion cell after 1 h equilibrium period. Occlusive 
conditions were used. The formulations remained in contact with the membrane 
on the donor side for 24 hours. Samples were taken from the acceptor medium 
(500 µL aliquots) after preset time intervals (1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 h) 
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and the volume of the acceptor medium was substituted with fresh medium. 
Concentration of the drug in the acceptor medium was determined by HPLC 
analysis (see Appendix). Release profiles were obtained by plotting the amount 
of BMV assayed in the acceptor medium in µg per unit area against the time. 
Studies were carried out in triplicate. 
  
3.2.2.4 Skin permeation studies  
Excised porcine ear skin from German domestic pigs was used for skin 
permeation studies. The viability of the skin is not a prerequisite for permeation 
testing, since the process depends on passive diffusion and there is no evidence 
for active transport (Diembeck et al., 1999). 
Pig ears were taken from the slaughterhouse (slaughterhouse Neidhardt, Holtsee, 
Germany). The pigs were slaughtered on the same day. Ears were cleaned with 
cold water and dried using soft tissue. Excessive hairs were removed through 
cutting and shaving. Skin from both sides from the ear was used. Skin was 
separated from the underlying cartilage and frozen at -25°C until further use. 
Drug permeation studies were performed in the analogical way as release 
studies. By plotting the amount of BMV permeated across the skin in µg per unit 
area against the time, permeation profiles were obtained.   
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4 Results and Discussions 
4.1 Development of a comprehensive approach for foam characterization 
The methods suggested by the Ph. Eur. 6.0 for foam characterization have some 
drawbacks. Specifically, the method for determination of foam expansion time is 
inapplicable for foams generated via mechanical pump systems or in situ. 
Moreover, this monograph does not consider determination of foam stability. 
Independent of the foam generation mechanism, evaluation of foam quality 
parameters in the addition to the information about foam stability is crucial for 
formulation development. Furthermore, an estimation of general foam 
appearance as well as stability and degree of expansion are essential factors for 
cosmetic acceptance. 
Limitations of the suggested methods and lack of a method for the determination 
of foam stability lead to the necessity to develop a new approach which can be 
used for routine analysis. This method should allow a fast and comprehensive 
determination of foam appearance, consistency and stability as well as 
formulation foamability independent of the foam generation mechanism.  
For simplification of data interpretation, it was decided to use simple solutions 
of foaming agents which showed good results in the test after Jellinek (see 
4.2.1.2). Tween® 20, Brij® 35, Tagat® O2, Tagat® L2 and Tagat® S2 were used 
as foaming agents at concentrations ranging from 1.0% to 5.0%. All foams were 
produced by means of the Airspray® foam dispenser. 
Cylinder method, Texture analyser method and light (back-) scattering method 
were compared to each other. These methods were evaluated in terms of 
significance, determination time and ease of operation.  
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4.1.1 Cylinder method 
4.1.1.1 Foam expansion 
Foam expansion is a parameter of formulation foamability. Higher foam 
expansion values are to strive for as it would result in higher foam volumes 
which can be produced from a defined volume of a foamable formulation. 
In the homologue series of three foaming agents (Tagat® row, chemically 
presenting esters of fatty acids with glycerol, containing 20 units of 
polyoxyethylene in the molecule) different values for foam expansion were 
determined. Compared to foam expansion values of Tagat® O2 and Tagat® L2, 
much lower values for Tagat® S2 were detected. Tagat® L2 showed better 
foamability than Tagat® O2. No dependency of foam expansion values from 
foaming agent concentration was observed (Figure 15).  
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Figure 15 Foam expansion within the Tagat® homologue series 
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Differences in the foaming capacity of these foaming agents from the Tagat® 
homologue series could be explained due to the differences in the flexibility of 
foaming agent molecules which are involved into stabilization of newly 
generated interfaces. The mobility of molecules of the foaming agent is the 
factor which influences the effectiveness of a surfactant as a foaming agent. The 
only difference in the chemical structure of the used foaming agents is the length 
of the fatty acid chain incorporated into the molecule and representing the 
lipophilic part of the molecule. The long chain (C18) of stearic acid is more rigid 
and less mobile than chains of oleic acid (C18, double bond) and lauric acid 
(C12). This leads to a less pronounced mobility of the molecules. Presence of 
oleic acid which has a double bond in the molecule structure seems to lead to a 
higher flexibility of the foaming agent molecules than that caused by the 
presence of stearic acid but lower than that caused by the presence of lauric acid. 
Presence of lauric acid in the structure of the foaming agent molecule leads to a 
higher flexibility of the molecules, formation of flexible lamellae and, therefore, 
higher values for foam expansion. Presence of the stearic acid in the structure of 
the foaming agent molecule leads to a formation of rigid lamellae and, therefore, 
low values for foam expansion. No concentration dependence was determined as 
all foaming agents were used above their CMC. 
Considering the data for adsorption velocity of these three foaming agents, 
Tagat® L2 is thought to show a faster surface occupation than Tagat® O2 and 
Tagat® S2 (see 4.1.1.4). 
The hypothesis about better foamability caused by low surface film rigidity due 
to presence of lauric acid in the structure of Tagat® L2 is supported through 
comparison of the foam expansion parameter of two other foaming agents also 
containing lauric acid in their structure. These foaming agents were Brij® 35 
(ether of lauric alcohol and 23 units of polyoxyethylene) and Tween® 20 (ester 
of lauric acid with sorbitol, containing 20 units of polyoxyethylene).  
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No differences in the foaming capacity of Tagat® L2, Brij® 35 and Tween® 20 
were observed (Figure 16). 
This is due to the same elasticity of the foaming agent film on the interface. The 
size of the hydrophilic part of a molecule seems to have only a minor effect on 
the foamability of the formulations.  
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Figure 16 Foam expansion of solutions produced with foaming agents containing 
lauric acid in their structure 
 
4.1.1.2 Foam volume stability 
Foam volume stability is a parameter indicating the stability of air bubbles 
incorporated into a foam structure against rupture. If the parameter of foam 
volume stability is high, air bubbles are more resistant to the process of bubble 
rupture.   
Considering the parameter of foam volume stability within the homologue 
Tagat® series, an opposite ranking of the foaming agents than during foamability 
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observations was found. The highest foam volume stability values were 
determined for Tagat® S2, the stearic acid ester of the series.  
Foam volume stability values of Tagat® O2 and Tagat® L2 were found to be 
much lower than that of Tagat® S2 whereas foam volume stability values of 
Tagat® O2 only were slightly higher than that of Tagat® L2 (Figure 17). No 
concentration dependence was determined.   
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Figure 17 Foam volume stability within the Tagat® homologue series 
 
Bubble rupture is connected with the elasticity / rigidity of the foaming agent 
film formed in the interface. When molecules of Tagat® S2 which contains 
steraic acid in its structure are adsorbed in the new interface, a rigid, low elastic 
film is build. This, on one hand, is the reason for low foam expansion (see 
4.1.1.1). On the other hand, the rigidity and inelasticity of the adsorbed film lead 
to the better stability of foam bubbles against rupture. Adsorption of the Tagat® 
O2 and Tagat® L2 molecules in the interface leads to the formation of a flexible, 
elastic films because of the low rigidity of lauric and oleic acid chains in the 
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structure of these foaming agents. This would lead to a more pronounced 
mobility of the molecules in the interface and, therefore, low stability of air 
bubbles against rupture.  
A concentration dependence could not be observed, probably because the 
foaming agents were used in concentrations above their CMC.  
Considering the foam volume stability of Brij® 35 and Tween® 20 against the 
foam volume stability of Tagat® L2, no differences in values for all three 
foaming agents could be seen (Figure 18). The length of the hydrophilic part of 
foaming agent molecules as well as presence of sorbitol or glycerol molecules in 
its structure seems to have no effect on the foam volume stability of the 
produced foams.  
 
Tagat L2 1%-5% Brij 35 1%-5% Tween 20 1%-5%
0
2
4
6
8
10
12
14
16
18
Fo
am
 v
ol
um
e 
st
ab
ili
ty
, %
 
Figure 18 Foam volume stability of foams produced with foaming agents containing 
lauric acid in their structure 
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4.1.1.3 Foam liquid stability 
Foam liquid stability is a parameter which reflects the intensity of liquid 
drainage. Low values for foam liquid stability indicate a low volume of liquid 
phase which was separated during the foam aging and, therefore, better foam 
stability. Foam drainage is a complicated process which is not fully understood 
(see 2.1.5). The drainage process is independent from bubble rupture (Bikerman, 
1973). The type of foaming agent is a factor which influences the flow of the 
liquid through individual lamellae channels (Koehler et al., 2004).  
Considering the data for foam liquid stability derived from the cylinder test, a 
slightly higher drainage rate was determined for the foam generated with Tagat® 
S2 as foaming agent. Slightly lower drainage intensity was determined for foams 
produced by means of Tagat® O2 and Tagat® L2 (Figure 19). Foams produced 
from solution of Tagat® S2 were shown to have a low foam expansion but high 
foam volume stability (foam stability against bubble rupture), (see 4.1.1.1 and 
4.1.1.2). This was explained through a high rigidity of foam lamellae. The air 
bubbles in the foam are stable and do not rupture, but the liquid drains, however, 
through the foam lamellae. This leads to higher values for foam liquid stability. 
Foams produced from solutions of Tagat® O2 and Tagat® L2 show high foam 
expansion but low foam stability against rupture because of high flexibility of 
molecules in the surfactant film which is adsorbed in the interface. The liquid in 
lamellae in this case is well bonded because of a good pronounced Marangoni 
effect. This leads to lower values of foam liquid stability and, therefore, lower 
liquid drainage. No differences for the liquid drainage rate were observed 
comparing the three different foaming agents containing lauric acid in their 
structure (Figure 20). The structure of the molecule and the length of the fatty 
acid chain seem to be among many other factors such as, e.g., bulk solution 
viscosity and surface film elasticity which influence liquid drainage. The effect 
of the chain length on foam drainage is pronounced to a lesser extent than on 
foam expansion and foam volume stability parameters.  
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Figure 19 Foam liquid stability within the Tagat® homologue series 
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Figure 20 Foam liquid stability of foams produced with foaming agents containing 
lauric acid in their structure 
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4.1.1.4 Adsorption velocity of foaming agents into the interface 
This investigation was used to correlate the data of foamability and foam 
stability with the velocity of foaming agent molecules to adsorb into the 
interface (see 3.2.1.7). 
The following data for the foaming agents involved into the cylinder test were 
obtained. 
Tagat® O2, Tagat® S2 and Brij® 35 molecules showed a slow velocity of 
interfacial adsorption (Figures 21, 22 and 23). After volume increase, through 
addition of foaming agent solution, no decrease of the surface tension was 
observed during the measurement time. In contrast, Tagat® L2 and Tween® 20 
molecules tend to a fast interfacial occupation (Figures 24 and 25). The 
reduction of surface tension below 40 mN·m-1 was observed directly after dosing 
of foaming agent solution into the droplet of water. The data for occupation 
velocity could, nevertheless, not be correlated with the data for formulation 
foamability or foam stability parameters. 
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Figure 21 Adsorption velocity of Tagat® O2 into the interface 
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Figure 22 Adsorption velocity of Tagat® S2 into the interface 
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Figure 23 Adsorption velocity of Brij® 35 into the interface 
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Figure 24 Adsorption velocity of Tagat® L2 into the interface 
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Figure 25 Adsorption velocity of Tween® 20 into the interface 
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4.1.1.5 Summary 
The cylinder test presents a test for the determination of formulation 
foamability, foam volume and foam liquid stability. The test can be carried out 
easily. It requires no specific equipment or materials. Results for foamability 
show low standard deviations of the data. This is not the case during 
determination of foam volume and foam liquid stability. 
The length of the fatty acid chain in the structure of a foaming agent seems to be 
a factor influencing foamability capacity of a formulation and foam volume 
stability. No significant differences for foaming agents were determined by 
evaluation of foam liquid stability. This is due to complex combination of 
factors influencing this process.  
The cylinder test can be used for fast routine analyses of foamability and foam 
volume stability in formulation studies. 
Droplet shape analysis was used in this study to get deeper insight into 
adsorption velocity and surface tension changes over time and, with this, to find 
a correlation to the data obtained with the cylinder test. 
Droplet shape analysis was found to be a useful tool to investigate such 
parameters as adsorption velocity and surfactant film elasticity. However, a 
direct correlation to the stability parameters derived from the cylinder test could 
not be found.  
 
4.1.2  Texture analyser 
4.1.2.1 Foam firmness 
The foam firmness was evaluated as the maximum penetration force during 
foam compression. Surface viscosity, bulk liquid viscosity, bubble size 
distribution and foam geometry are among the factors which influence foam 
firmness (Wijnen, 1997). Considering the data for foam firmness for the Tagat® 
homologue series, slightly higher values were determined for Tagat® O2.  
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No differences were observed between foams produced from Tagat® L2 and 
Tagat® S2 solutions (Figure 26). The foam which was produced from a Brij® 35 
solution showed the highest values for foam firmness compared to the other two 
foaming agents containing lauric acid chain in their structure (Figure 27). Values 
for foam firmness for Tagat® L2 and Tween® 20 were similar. The higher values 
for Tagat® O2 and Brij® 35 foam were probably caused by the smaller bubble 
size or the higher gas volume fraction of the foam produced from these foaming 
agents. Smaller air bubbles execute more resistance during the compression 
cycle than larger bubbles, leading to higher values for foam firmness. 
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Figure 26 Foam firmness within the Tagat® homologue series 
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Figure 27 Firmness of foams produced with foaming agents containing lauric acid in 
their structure 
 
No correlation between foam firmness and concentration of foaming agent was 
observed. This is again a confirmation that viscosity of the foaming agent 
solution does not affect the foam firmness as determined with the Texure 
Analyser.  
 
4.1.2.2 Cohesiveness 
Foam cohesiveness was determined as the minimum force when the sample was 
proceeded to withdraw from the disk. Foam cohesiveness corresponds to the 
force which is required to overcome foam stickiness. The same rank order of 
foaming agents involved into the test was observed for foam cohesiveness as 
already reported for firmness. The highest values were determined for foams 
produced from Tagat® O2 and Brij® 35 solutions (Figure 28 and 29). Higher 
values for cohesiveness for these foaming agents are probably based on worse 
wettability of the compression disc surface with solutions of these foaming 
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agents. The worse wettability can be explained by the high gas volume fraction 
of foams produced from Tagat® O2 and Brij® 35 solutions. This supposition 
correlates with the data for foam firmness.  The cohesiveness values for Tagat® 
L2, Tagat® S2 and Tween® 20 were similar. No concentration dependence for 
cohesiveness values was observed.  
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Figure 28 Foam cohesiveness within the Tagat® homologue series 
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Figure 29 Cohesiveness of foams produced with foaming agents containing lauric 
acid in their structure 
 
4.1.2.3 Summary 
Foam firmness in this study was determined as the maximum resistance of a 
foam against a standardised deformation (compression). It was possible to 
determine foam firmness and foam cohesiveness with the Texture analyzer 
method. These two parameters of foam quality were brought in connection with 
foam bubble size and foam gas fraction. This method is time-intensive and, in 
case, the foam structure is inhomogeneous, the measurements are not possible. 
Large air bubbles within the foam disrupt the measurement causing irregularities 
in the texture analyser force profile. However, the mechanical properties derived 
from the force-time curve can be used to assess the application ease of foam 
samples and adhesiveness of foam to the skin.  
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4.1.3  Light (back-) scattering method 
4.1.3.1 Backscattering profiles 
The backscattering signal correlates with the growth of foam air bubbles which 
takes place as foam ages. Foam bubble growth taking place because of Ostwald 
ripening has nothing in common with bubble rupture which can be observed by 
means of FVS measurement with the cylinder test. Bubble rupture during light 
(back-) scattering method can be observed through a decrease of the foam 
meniscus in the measuring cell over the determination time.  
Considering the data for the Tagat® homologue series, foams produced from 
Tagat® S2 showed a growth of air bubbles which was more pronounced 
compared to foams produced from Tagat® O2 and Tagat® L2. Foams produced 
from Tagat® L2 showed the lowest air bubble growth observed during 
determination time (Figure 30). 
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Figure 30 Delta Backscattering within the Tagat® homologue series 
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Figure 31 Delta Backscattering of foams produced with foaming agents containing 
lauric acid in their structure 
 
Considering bubble growth of foaming agents which contain lauric acid in their 
structure, it was more pronounced by use of Tween® 20 as foaming agent. No 
differences between foams produced from Tagat® L2 and Brij® 35 were 
observed (Figure 31). It can be concluded that Ostwald ripening happens to a 
greater extent in foams produced from Tagat® S2 and Tween® 20 as foaming 
agents.   
 
4.1.3.2 Transmission profiles 
The intensity of the transmission signal should correlate with the data for foam 
liquid stability obtained with the cylinder test. In both cases, liquid drainage is 
evaluated. The results were, nevertheless, different from that obtained by the 
cylinder test. Liquid drainage of the foams produced from Tagat® S2 solutions 
was less pronounced than liquid drainage observed for foams produced from 
Tagat® O2 and Tagat® L2 solutions (Figure 32). Liquid drainage, observed by 
4 Results and Discussions 
 98
the foam produced from Tagat® L2 solution was more pronounced than liquid 
drainage from foams produced from Brij® 35 and Tween® 20 solutions (Figure 
33).  
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Figure 32 Delta Transmission within the Tagat® homologue series 
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Figure 33 Delta Transmission of foams produced with foaming agents containing 
lauric acid in their structure 
 
4.1.3.3 Summary 
The light (back-) scattering method provides a fast and practical approach to 
characterize foam stability through detection of air bubble growth and liquid 
separation because of liquid drainage in a foam. Foamability of a formulation 
can, nevertheless, not be detected with this method. To detect foamability, the 
cylinder test described before, presents a timesaving alternative.  
 
4.1.4  Comparison of methods 
Three methods were used for comprehensive foam characterization. A 
comparison of these methods according to their significance, determination time 
and ease of operation is given in Table 11. 
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Table 11 Foam characterization: comparison of methods 
Method Parameter Significance Determination  
time 
Ease  
of operation 
Foamability + + + 
FLS ± + + 
Cylinder 
method 
 FVS ± + + 
Firmness + + ± Texture 
Analyser Cohesiveness + + ± 
Bubble growth + + ± Turbiscan 
method Liquid drainage ± + ± 
+ good           ± acceptable           - poor 
 
The cylinder method requires short determination time and is very easy to carry 
out. During the determination of foam firmness and cohesiveness by means of 
the Texture Analyser and transmission and backscattering signals by means of 
the light (back-) scattering method experimental skills are required for foam 
discharge into the measuring vessel. Incorporation of big air bubbles should be 
avoided, as it can lead to disruption of the force-time curve in the Texture 
Analyser method and increased transmission values in the light (back-) 
scattering method. Short determination times are required for these kinds of 
analysis. Determination of liquid drainage through transmission is not possible 
for foams produced from highly opaque solutions, as it leads to low transmission 
intensities.     
 
4.1.5  Recommendation of a comprehensive approach for foam 
characterization  
A comprehensive approach for foam characterization was developed. The 
proposed approach presents a time saving alternative to the methods proposed 
by Eur. Ph. 6.0. Moreover, the developed methods consider the determination of 
foam stability which is not included in the Eur. Ph. The methods are easy to 
carry out, nevertheless, certain experimental skills are required. The methods are 
supposed to be used in routine analysis for the formulation development stage. 
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The following set of tests is proposed. It is proposed to determine foamability of 
formulations with the cylinder method. Foam firmness and cohesiveness can be 
determined using the Texture Analyser method. Foam stability caused by liquid 
drainage can be determined through observation of transmission intensities by 
means of the light (back-) scattering method, if the drained solution is not 
opaque. In case of opaque solutions, liquid drainage can be determined through 
calculation of FLS from the cylinder method. Foam bubble rupture can be 
determined through FVS by means of the cylinder method. The increase of the 
foam bubble size can be determined through observation of backscattering 
intensities using the light (back-) scattering method. The combining of these 
analytical techniques for foam characterization allows for a fast and extensive 
screening of potential formulation candidates as well as for routine drug product 
quality control.   
 
4.2 Formulation development 
4.2.1  Development of a low viscous O/W emulsion 
4.2.1.1 Optimum viscosity for the foam generation with the Airspray® 
foam dispenser 
High viscous liquids can not be foamed by means of Airspray® foam dispenser 
because the process of mixing the formulation with air in the metering chamber 
is complicated due to the high viscosity. This leads either to failure of foam 
generation or to the generation of an inhomogeneous foam. Therefore, the 
optimum viscosity interval for foam generation had to be determined. Sodium 
lauryl sulfate (Texapon K 12) dissolved in water at a concentration of 0.5% was 
used as a model foaming agent for these investigations. Hydroxypropyl methyl 
cellulose (Metolose 60 SH 50) at concentrations from 0 to 3.0% was added to 
the solution of the foaming agent and used as a standard gelling agent for foam 
stabilization. Foam was generated using Airspray® dispenser and foam density 
(determination according to Ph. Eur. 6.0) and foam expansion parameters were 
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determined which are appropriate indicators for foamability. The complex 
viscosity of the solutions was measured by oscillation rheometry. A dependence 
between solution viscosity and foam quality was observed and the optimal 
viscosity interval for this kind of foam generator was determined: At HPMC 
concentrations of 1.0-1.2%, an increase in foam density was observed (Figure 
34). Higher values for foam density indicate a low gas volume fraction in the 
foam and correlate with fast destabilization of the foam.  
At the same HPMC concentrations a reduction of foam expansion was observed 
(Figure 35) which can be taken as an indicator for a worsened foamability of 
formulations. The optimum values for foam expansion were observed at HPMC 
concentrations of 0.4%-0.8%. By means of this test, an upper viscosity limit for 
the Airspray® dispenser was determined. It was defined to be approximately 
30 mPa·s (equates to the HPMC concentration of 1.2%). 
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Figure 34  Influence of polymer concentration on foam density and complex viscosity 
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Figure 35 Influence of polymer concentration on foam expansion and complex 
viscosity 
 
At higher viscosity an effective passage of the formulation through the double 
sieve is hindered or completely impossible. In the first case, it leads to 
production of a foam with high foam density and, therefore, a low gas volume 
fraction which leads to a decreased foam stability. In the second case, no foam 
production takes place.   
The optimum viscosity interval was, therefore, determined to be between 3 and 
30 mPa·s which equates to HPMC concentrations of 0.2 to 1.2%.  
   
4 Results and Discussions 
 104
4.2.1.2 Foaming agents 
The ability of different surfactants to foam was screened with the foamability 
method after Jellinek (1959). Shaking was used as a foam generation method. 
The results of this preliminary test are summarized in the Appendix.  
All anionic surfactants involved at concentrations from 1% to 5% showed good 
foamability and foam stability after 15 and 30 min (scale values between 7 and 
3). Nevertheless, nonionic agents were preferred as the toxicity potential of 
these substances is reported to be lower than that of anionic surfactants. The 
irritant potency e.g. of Tween® 20 was shown to be lower than that of sodium 
lauryl sulfate (Effendy and Maibach, 1996). Using Hostapon®, Medialan®, 
Serwet® WH 172 and Rewopol® SB CS 50K as foaming agents led to production 
of a very stable fine pored foam which was stable over the whole test period. 
However, the best foamability and foam stability was obtained with sodium 
lauryl sulfate. These observations supported the information that anionic 
surfactants are good foaming agents. Moreover, all surfactants from the anionic 
group are widely used for cosmetic application but are not approved for 
pharmaceutical application yet (with the exception of sodium lauryl sulfate). 
Therefore, it was decided to decrease the number of surfactants in the study to 
those surfactants which are approved for pharmaceutical use. Polyoxyethylene 
containing surfactants (Tagat®- series, Brij®- series and Tween®- series) with 
different length of fatty acid side chains in their structure were chosen for 
further investigations. Especially Tagat® L2, Brij® 35 and Tween® 20, all three 
containing the ester of lauric acid, showed good values for foamability (see 
Appendix).  
The rule after Traube corroborates these findings. This experimental rule 
postulates that the velocity of the interfacial occupancy correlates with the 
length of the fatty acid side chain in the structure of a homologous series of 
surface active substances. The longer the fatty acid side chain, the faster the 
interface will be occupied with the surfactant molecules and, therefore, the faster 
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the CMC is reached in a solution, because formation of micelles is 
thermodynamically preferred for these molecules. In the case of shorter fatty 
acid side chains occupation of the interface would take place more slowly. For 
foam production, when a huge interface is created in a short period of time, slow 
occupation of newly created interfaces may be beneficial. The series of the 
foaming agents used in this test contained stearic acid (C18), oleic acid (C18, 
double bond), cetyl alcohol (C16), palmitic acid (C16) and lauric acid (C12). 
Lauric acid contains the shortest hydrocarbon chain, leading to a lower CMC 
and, therefore, to better values of foamability.  
A shorter fatty acid side chain leads to a slow occupation / enrichment in the 
interface according to the rule after Traube. However, a shorter fatty acid chain 
length causes more flexibility and diffusivity of the molecule. The latter 
characteristic is in this case considered to be dominant over the CMC because 
diffusivity in the interface and film flexibility are more relevant to foam 
stability. Tween® 20, Brij® 35 and Tagat® L2 were chosen for further 
formulation development.  
 
4.2.1.2.1 CMC of foaming agents 
Foaming agents should be used in concentrations above their CMC. For three 
surfactants which were chosen in the preliminary test for further investigations 
(Tween® 20, Brij® 35 and Tagat® L2), the CMC was determined by means of 
plotting the surface tension of surfactant solution vs. surfactant concentration  
(n=3), (Figure 36). 
For these foaming agents, the CMC was determined to be in the range of 0.02% 
to 0.03% which is in accordance to literature data.  
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Figure 36 Critical micelle concentration of foaming agents (SD are too low to be seen 
on the plot; graphical CMC determination is not shown) 
 
4.2.1.3 Foam stabilizing agents  
Concentrations of foam stabilizing agents were determined analogically to the 
optimum viscosity determinations for the foam generation with the Airspray® 
dispenser (see 4.2.1). The complex viscosity was determined with oscillation 
rheometry. HPMC was used at concentrations of 0.4%, 0.6%, 0.8% and 1.0%. 
MC was used at concentrations of 0.1%, 0.2 and 0.4%. Xanthan gum was used 
at a concentration of 0.05%. Also, combinations of two foam stabilizing agents 
such as HPMC / Xanthan (0.6% / 0.01%) and MC / Xanthan (0.2% / 0.01%) 
were used. It was assured with oscillation measurements that the use of the 
respective surfactant / polymer combination did not lead to a solution complex 
viscosity of more than 30 mPa·s. 
The surface tension of the foam stabilizing agents was determined by means of 
tensiometry. The results are summarized in Table 12. 
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Table 12 Surface activity of foam stabilizing agents 
Polymer concentration, % Surface tension, mN·m-1 
mean ± SD 
HPMC 1.0% 46.2 ± 0.1 
MC 0.4 % 45.1 ± 0.6 
Xanthan 0.05% 58.3 ± 0.5  
HPMC 0.6% / Xanthan 0.01% 44.6 ± 0.1 
MC 0.2% / Xanthan 0.01% 44.4 ± 0.3 
 
It is desired for foam stabilization that foam stabilizing agents have an affinity to 
occupy the interface. The chosen polymers have this affinity which can be 
observed through the reduction of surface tension. The highest HPMC and MC 
concentrations used for further stabilization studies, namely 1.0% and 0.4% 
respectively, as well as combinations of these polymers with xanthan gum  led 
to a reduction of the surface tension of approximately 27 mPa·s. Xanthan gum 
alone also has an affinity to occupy the interface, which is, nevertheless, 
pronounced to a lesser degree.  
 
4.2.1.3.1 Effect of different foam stabilizing agents / combinations of 
foam stabilizing agents on foam quality 
Solutions containing 3% Tween® 20 and optimized polymer concentrations (see 
4.1.2) or their combinations were produced.  The foams were generated by 
means of the Airspray® dispenser. The cylinder test was performed in triplicate. 
Foam density was not determined as it was supposed to be similar for all used 
foam stabilizing agents (FSA), as the complex viscosity of the formulations 
were held approximately at the same level. Results are summarized in Figure 37, 
38, 39 and 40, respectively.  
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Figure 37 Foam expansion of Tween® 20, 3% solution under the influence of 
different foam stabilizing agents 
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Figure 38 Foam volume stability of Tween® 20, 3% foam under the influence of 
different foam stabilizing agents 
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Figure 39 Foam liquid stability of Tween® 20, 3% foam under the influence of 
different foam stabilizing agents 
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Figure 40 Gas fraction of Tween® 20, 3% foam under the influence of different foam 
stabilizing agents 
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Figure 41 Complex viscosity depending on polymer concentration 
 
The foam expansion of a 3% Tween® 20 solution was shown to be influenced 
only marginally through the addition of stabilizing agents or their combinations 
within the limits of optimal solution viscosity. Slightly higher values for foam 
expansion were observed while using MC, xanthan gum and polymer 
combinations as foam stabilizing agents. This data is in accordance to the 
surface activity of these polymers (Table 13), with exception of xanthan gum, 
but do not correlate to the viscosity of the solutions (Figure 41). This is an 
indication that foam expansion does not depend on the solutions’ viscosity, as 
foam stability does, but is more connected to the nature of a foam stabilizing 
agent.   
Higher values for foam volume stability should be aimed at as in this case foam 
destabilization mechanisms are slowed down. Slightly higher values for foam 
volume stability were determined while using xanthan and polymer 
combinations and slightly lower values while using MC as foam stabilizing 
agents (Figure 38). 
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The velocity of foam destabilization is directly dependent on the viscosity of 
solutions. Solutions’ viscosity while using MC is in the range of 6 to 8 mPa·s 
which seems to be a disadvantageous range for liquid drainage. The same trend 
is observed for foam liquid stability. Low values for this parameter are 
indicators for slow liquid drainage and, therefore, good foam stability. With 
MC, especially in concentrations of 0.2% and 0.6%, nearly twice as high values 
for foam liquid stability were observed compared to the application of other 
polymers or without polymer application (Figure 39).       
While using xanthan gum alone, slightly higher values for foam volume stability 
and lower values for foam liquid stability were observed than compared to the 
other polymers. It seems that the presence of xanthan gum in the formulation 
would slow down the processes of foam destabilization. The reason for better 
foam stability in presence of xanthan gum may be its low surface activity. 
HPMC and MC as surface active substances compete against molecules of 
foaming agent in the interface. This competition for the interfacial occupation 
leads to a decreased foam stability. Xanthan gum being a substance with low 
surface activity does not practice this kind of competition. Its presence, 
therefore, leads to a better foam stability.   
Considering the gas fraction of produced foams no definite trends through 
application of foam stabilizing agents could be observed (Figure 40). All values 
were in the range of 19.5 mL ± 1.9 mL. The gas fraction parameter is desired to 
be high as it indicates a high gas amount incorporated into the foam and, 
therefore, lowers the velocity of foam destabilization mechanisms based on 
gravitational force such as liquid drainage. 
According to the results xanthan gum 0.05% as well as combinations of HPMC 
0.6% / xathan gum 0.01% and MC 0.2% / xanthan gum 0.01% were chosen for 
further formulations studies.  
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4.2.1.3.2 Effect of a foam stabilizing agent on foam characteristics 
produced from three different foaming agents  
In this part of the study, HPMC 0.4% – 1.0% was used to investigate the 
influence of a stabilization agent on the foam characteristics produced from 
three different foaming agents: Tween® 20, Brij® 35 and Tagat® L2. 
Concentration of foaming agents was held at 3% (0.024 mol/L, 0.025 mol/L and 
0.026 mol/L respectively). These foaming agents were chosen as they showed 
good results in the foaming test after Jellinek (1959), (see 4.2.1.2). Considering 
foamability characteristics (foam expansion) and foam stability characteristics 
(foam volume stability, foam liquid stability and gas fraction) of these three 
foaming agents without addition of HPMC, the following rank order was 
determined: Tween® 20 performed slightly better than Tagat® L2 and Brij® 35. 
The same trend can be observed for these foaming agents considering 
foamability characteristics under addition of HPMC, whereas differences 
between Brij® 35 and Tagat® L2 by the addition of 0.8% and 1.0% HPMC 
cannot any more be observed (Figure 42). The same ranking of the foaming 
agents was observed considering the plot of gas fraction in produced foams 
(Figure 43).  
Since gas incorporation into the foam structure happens during the process of 
foam generation, this trend was expected. 
Better values for Tween® 20 and Tagat® L2 could be explained based on the 
chemical structure of these foaming agents as these foaming agents were used in 
the same molar concentration. Moreover, they have similar molecular weight 
(Tween® 20 1276 g·mol-1, Brij® 35 1198 g·mol-1 and Tagat® L2 1154 g·mol-1), 
similar HLB values and are used in concentrations above CMC.      
Different chemical structures of these foaming agents, such as longer 
polyethylene oxide chain within the structure of Brij® 35 structure or presence of 
hydrophilic units such as sorbitane and glycerol in the structure of Tagat® L2 
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and Tween® 20, can lead to different velocities of the interfacial occupation 
during the process of interface generation during foam production.  
The parameter of foam volume stability describes a process of air bubble 
coalescence and, therefore, reduction of height of the foam column. This process 
seems to be independent from the viscosity of a formulation, as nearly no 
differences or no trend were observed considering the parameter of foam 
volume stability (Figure 44).    
Foam liquid stability, on the other hand, is directly dependent on the viscosity. 
Liquid separation from foam structure (liquid drainage) processes slower at 
higher viscosities of foamable solutions. 
Through addition of HPMC, viscosity of colloidal solutions increases. The 
increase of viscosity leads to a slowdown of liquid drainage which results in a 
decrease of the foam liquid stability. This can clearly be followed by addition of 
HPMC to Brij® 35 and Tween® 20 solutions (Figure 45).  
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Figure 42 Foam expansion of 3% solution of three different foaming agents under 
the influence of HPMC 
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Figure 43 Gas fraction of three different foaming agents, 3%, under the influence of 
HPMC 
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Figure 44 Foam volume stability of three different foaming agents, 3%, under the 
influence of HPMC 
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Figure 45 Foam liquid stability of three different foaming agents, 3%, under the 
influence of HPMC 
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4.2.1.4 Oil phase 
Viscosity and polarity of the oil phase in emulsions have an influence on the 
emulsion stability. Liquid oils from different chemical groups and different 
origin were used for formulation development and classified according to their 
viscosity and polarity. The viscosity of the emulsion should not exceed the 
upper limit of 30 mPa·s.  
 
4.2.1.4.1 Viscosity of the oil phase 
Viscosity values of oil components are summarized in Figure 46. Abil® 100, 
olive oil and soybean oil showed the highest viscosity values whereas viscosity 
values of isopropyl palmitate, isopropyl myristate and cyclomethicone were 
comparatively low. 
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Figure 46 Viscosity of oil components 
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Figure 47 Interfacial tension between oil components and water 
 
4.2.1.4.2 Polarity of the oil phase 
The polarity values reported as the interfacial tension between water and the 
respective oil are summarized in Figure 47. High values for the interfacial 
tension between water phase and oil phase point to the low polarity of the 
respective oil. The oils were classified as polar when the interfacial tension 
values were lower than 25 mN·m-1 (see 3.2.1.4). Interfacial tension between 
water and such oils as paraffin oil and Abil® 100 were the highest. This indicates 
a low polarity of these oils. Contrary, olive oil and Miglyol® 812 showed 
comparatively high polarity. 
The following oil components were used for further formulation development 
(Table 13). This choice was based on the combination of polarity and viscosity 
values to evaluate the influence of different oil properties on emulsion stability.  
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Table 13 Oil components for further formulation development 
Parameter 
Polarity Viscosity 
Oil component 
 
   
Nonpolar High viscosity Abil® 100 
   
Nonpolar Low viscosity Paraffin oil 
   
Polar High viscosity Olive oil 
   
Polar Low viscosity Miglyol® 812 
   
Polar Low viscosity Cyclomethicone 
   
 
4.2.1.4.3 O/W emulsions and their characteristics 
The basic composition for a foamable o/w emulsion is presented in Table 14. 
The choice of foaming agents and foam stabilizing agent was based on 
preliminary tests as described earlier (see 4.2.1.2 and 4.2.1.3).  
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Table 14 Basic composition for a foamable o/w emulsion 
Phase    Component    Amount 
Oil phase    e.g. Miglyol® 812   0.1% - 1.0 % 
       
Foaming agent   e.g. Tween® 20   5.0% - 10.0 % 
Foaming agent blend (1:1)    
(emulsifier)  
(solubilization agent) 
 
Co-emulsifier   e.g. Span® 20   1.0% - 4.5% 
 
Emulsion stabilization agent e.g. Pemulen® solution 0.1% 1.0%   
 
Foam stabilization agent e.g. HPMC     0.4% - 1.0% 
 
Preservative agent  Sodium benzoate   0.1% 
 
Topical corticosteroid  BMV     0.025% - 0.1% 
 
Phosphate buffer pH 4.5      q. s. ad 100%  
 
 
Formulation development was proceeded with the foaming agents containing 
lauric acid chain rests in their structure, namely Tween® 20, Brij® 35 and Tagat® 
L2 or combinations thereof. HPMC (0.4%-1.0%), MC (0.1%-0.4%), xanthan 
gum in concentrations up to 0.05% and combinations of two stabilizing agents 
were used for foam stabilization. All combinations were produced and evaluated 
due to their optical appearance. The stability of the produced emulsions was 
examined with the centrifuge test and a high temperature-low temperature cycle 
test. The appearance of the emulsions after stability tests was evaluated by 
means of the scheme after Quack et al. (1975). Emulsions evaluated with note 8 
were assessed as stable (see 3.2.2.2.2.). It was possible to produce stable low 
viscous emulsions with the following components and their fractions (Table 15). 
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Table 15  Compositions of stable low viscous o/w emulsions 
Phase     Component   Amount 
Oil phase     Miglyol® 812  0.1% - 1.0 % 
       
Foaming agent    Tween® 20   7.0%  
Foaming agent blend (1:1)  Brij® 35  
(emulsifier)     Tagat® L2    
(solubilization agent)   Tween® 20 : Brij® 35 
 
Foam stabilization agent  HPMC    1.0% 
      MC    0.4% 
      HPMC / Xanthan gum 0.6% / 0.01% 
      MC / Xanthan gum 0.2% / 0.01% 
      Xanthan gum  0.03% - 0.05% 
       
 
Preservative agent   Sodium benzoate  0.1% 
 
Topical corticosteroid   BMV    0.025% - 0.1% 
 
Phosphate buffer pH 4.5      q. s. ad 100%  
 
 
Surfactants or their blends were used in the formulation for following purposes: 
- as solubilization agent for BMV 
- as emulsifier 
- as foaming agent. 
Relatively high amounts of surfactant were essential to solubilize BMV 
(preliminary test, data not shown). At the same time, it was possible to 
incorporate up to 1% of a low viscous polar oil (Miglyol® 812) into the 
formulation. The concentration of foam stabilizing agents could not be further 
increased because of the upper viscosity limit of the Airspray® dispenser. 
Addition of w/o emulsifiers such as Span® 20, Span® 60, Span® 80 and Brij® 72 
at a low concentration did not result in stable formulations. Addition of these co-
emulsifiers in concentrations up to 4.5% led to an increase of formulation 
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viscosity so that it was not possible to produce a foam. The use of emulsion 
stabilizing agents such as Pemulen® or Carbopol® (solutions 0.1%) also led to a 
viscosity increase.   
The droplet size distribution of the oil phase of produced emulsions was in the 
range of 134.3 ± 1.5 to 320.5 ± 5.6 nm (nanoemulsions) which is typical for 
emulsions produced with the ultra-turrax method (Urban et al., 2006). 
Moreover, a bimodal particle size distribution was observed. Particles with a 
size in the range of 6.9 ± 0.3 nm were attributed to the size of the micelles of 
surface active substances. This is in accordance to the literature data 
(Kumbhakar et al., 2004; Chumakov et al., 2006).  
 
4.2.1.4.4 Influence of the oil component on foam quality   
Foamability, foam stability characteristics and firmness of foams produced from 
stable emulsions were evaluated (Table 16). Formulations of the same polymer-
surfactant composition but without an oil fraction were also produced to 
investigate the influence of the oil component on foam quality. BMV was also 
excluded from the composition. 
 
Table 16 Foam quality produced from o/w emulsions and formulations without oil 
phase 
Characteristics, 
mean ± SD 
O/W emulsion Without oil fraction 
FE, [%] 1095.5 ± 111.1 1077.9 ± 43.4 
FVS, [%] 43.3 ± 5.8 94.4 ± 2.4 
FLS, [%] 87.6 ± 5.2 43.1 ± 4.5 
GF, mL 19.5 ± 0.6 20.3 ± 0.6 
Foam firmness, [g] 25.3 ± 2.5 24.8 ± 1.8 
Liquid drainage, [mm·min-1] -2.63 ± 0.25 -1.82 ± 0.23 
Bubble growth, [%·min-1] 0.92 ± 0.04 0.59 ± 0.02 
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Foamability of formulations as well as foam firmness was not influenced 
through addition of an oil phase. Nevertheless, an almost 50% decrease of foam 
stability (liquid drainage from FLS and height of foam column from FVS, 
cylinder test) was observed.   
The light (back-) scattering method showed similar results. The liquid drainage 
rate of the emulsion was higher compared to the oil free formulation. The bubble 
growth rate of the emulsion also had higher values than the bubble growth rate 
of the oil free formulation. 
The reduced stability of foams produced from emulsions can be explained 
through the presence of the oil phase. Oil droplets orientate themselves at the 
foam lamellae which leads to an increase of surface pressure and reduction of 
film elasticity. This ends up in the reduction of foam stability (Roberts et al., 
1975).  
 
4.2.1.4.5 Influence of foaming agent combinations on foam quality 
The influence of foaming agent combinations on foam quality was investigated 
using the example of an o/w composition with 10% foaming agent fraction. 
The results are summarized in Table 17. 
 
Table 17 Foam quality produced from o/w emulsions with single and combined 
foaming agent fraction 
Characteristics, 
mean ± SD 
Tween® 20 
10% 
Tween® 20 : 
Brij® 35 (1:1) 
10% 
Tagat® L2: 
Brij® 35 (1:1) 
10% 
FE, [%] 1095.5 ± 99.1 986.3 ± 4.7 991.3 ± 22.6 
FVS, [%] 43.3 ± 5.8 62.1 ± 2.1 43.4 ± 0.6 
FLS, [%] 87.6 ± 5.2 74.4 ± 3.5 81.5 ± 7.1 
GF, mL 19.5 ± 0.6 19.1 ± 0.5 19.6 ± 0.6 
Foam firmness, [g] 25.3 ± 2.5 24.3 ± 2.1 25.6 ± 2.3 
Liquid drainage, [mm·min-1] -2.63 ± 0.25 -2.21 ± 0.20 -2.58 ± 1.89 
Bubble growth, [%·min-1] 0.92 ± 0.04 0.75 ± 0.05 0.89 ± 0.04 
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The use of a Tween® 20 : Brij® 35 (1:1) combination in the composition of the 
foamable o/w emulsion led to an increase of FVS and a decrease of FLS and, 
therefore, to a better foam stability. This phenomenon is also described by 
Jellinek (1959). Other parameters were not changed through a combined 
foaming agent application.  
 
4.2.1.5 ’’Dose uniformity’’ of the Airspray® foam dispenser 
The Airspray® foam dispenser was tested considering its ability to deliver 
uniform doses of the corticosteroid. Three different concentrations of BMV 
were used for this test (0.025%, 0.05% and 0.1%). Each concentration was 
tested with three dispensers. Three actuations of dispenser pump dosing system 
were performed with each dispenser. The results are presented in Figure 48 and 
49. It was possible to deliver a uniform amount of BMV using the Airspray® 
foam dispenser.  
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Figure 48 Amount of BMV per pump actuation 
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Figure 49 Formulation amount per pump actuation 
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4.2.1.6 Microscopic evaluation of skin status after application of a foam 
vehicle 
To identify possible residues of the foam vehicle after application on the skin 
surface, microscopic imaging was performed. The foam vehicles are expected to 
leave little residue on the skin surface after application as fluid foam 
components evaporate. Residues may consist of oil components and surfactants. 
For this test a composition with the highest oil and surfactant faction was 
chosen. A foam vehicle was applied onto a cleaned dry surface of the hand. The 
vehicle was distributed on the surface and the skin was dried at room 
temperature for approximately 1 min at ambient humidity. The skin area where 
the formulation was distributed was visually compared to untreated area. No 
differences between these two areas were detected (Figure 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Results and Discussions 
 126
 
Figure 50 Microscopic assessment of skin surface: 
  A. Before application of foam vehicle 
B. After application of foam vehicle 
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4.2.2  Solution based foams 
4.2.2.1 Formulation development steps 
The solubility of BMV in different solvents (see 3.1.4) was determined as 
described in 3.2.1.5. As BMV was dissolved, it was possible to reduce the 
foaming agent fraction. Combined surfactant use was also abdicated. Foamable 
formulations of the following compositions were produced (Table 18). All 
combinations were tested. These formulations passed through temperature and 
centrifuge stress stability tests. 
 
Table 18  Compositions for foamable solutions of BMV 
Phase     Component   Amount 
Solvent     Propylene glycol  ≥ 11.3% 
      Hexylene glycol  ≥ 5.6% 
      Pharmasolve®  ≥ 0.8% 
      Arlasolve®   ≥ 1.9%  
       
Foaming agent    Tween® 20   3.0%  
 
Foam stabilization agent  HPMC    1.0% 
      MC    0.4% 
      HPMC / Xanthan gum 0.6% / 0.01% 
      MC / Xanthan gum 0.2% / 0.01% 
      Xanthan gum  0.03% - 0.05% 
       
 
Preservative agent   Sodium benzoate  0.1% 
 
Topical corticosteroid   BMV    0.1% 
 
Phosphate buffer pH 4.5      q. s. ad 100%  
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4.2.2.2 Evaluation of formulation stability 
Foam stability was determined by means of the light (back-) scattering method. 
Formulations containing HPMC at a concentration of 1.0% and xanthan gum at 
a concentration of 0.05% as foam stabilizing agents and different solvents for 
BMV in minimal possible concentrations to dissolve BMV (see Table 18) were 
compared to each other. The results are summarized in Figure 51, 52, 53 and 54, 
respectively. 
Considering the rate of foam bubble growth and the rate of liquid drainage, no 
effect of different solvents on foam stability was observed, whereas the solvents 
were used in different concentrations. In contrast, different foaming agents were 
shown to have an effect on these parameters. The foams with xanthan gum as 
foam stabilizing agent showed a growth of air bubbles which was pronounced to 
a lesser degree than by the foams produced with HPMC as foam stabilizing 
agent. The liquid drainage rate was also determined to be lower for the foams 
with xanthan gum. This phenomenon was already discussed in 4.2.1.3.1.   
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Figure 51 Foam bubble stability (foams with 1.0% HPMC) 
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Figure 52 Foam bubble stability (foams with 0.05% xanthan gum) 
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Figure 53 Liquid drainage rate (foams with 1.0% HPMC) 
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Figure 54 Liquid drainage rate (foams with 0.05% xanthan gum) 
 
4.2.3  Summary 
It was shown during the preliminary tests that foamability of different foaming 
agents and their combinations as well as foam stability characteristics could be 
influenced through the addition of polymers. High concentrations of polymers 
causing an increase of viscosity above 30 mPa·s should be avoided. This leads to 
a worse foamability of formulations because of the construction of the Airspray® 
foam generator. Foam stability can be increased through the addition of low 
concentrations of polymers or their combinations. The differences between 
polymers in their capacity for foam stabilization could be explained through 
their different surface activity. 
The Airspray® dispenser was shown to be an appropriate device for foam 
generation for pharmaceutical needs. The dispenser is able to deliver uniform 
doses of the corticosteroid within the generated foam. 
Stable low viscous o/w emulsions were produced using a low viscous polar oil 
such as Miglyol® 812 as an oil phase. Surfactants containing lauric acid and 
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combinations thereof were used as foaming agents and emulsifiers. BMV was 
solubilized by means of the same surfactants. The produced emulsions were 
nano-emulsions which was reached by the method of high-energy emulsification 
(high-shear stirring with ultra turrax). Sufficient formulation stability during 
storage as well as delivery of the equivalent active ingredient dosage within the 
application was assured. Incorporation of oil into compositions of foamable 
formulations resulted in reduced stability of foams. The combined use of two 
foaming agents led to better values of foam stability of produced of o/w 
emulsions. Application of the emulsions onto the skin resulted in no visual 
residues. 
By the production of solution based foamable formulations, BMV was dissolved 
in different solvents. Such solvents as propylene glycol, hexylene glycol, 
Pharmasolve® and Arlasolve® were used. The use of ethanol as solvent was 
avoided as it may enhance drug penetration into the skin leading to undesired 
side effects. The presence of ethanol in the formulation may also lead to skin 
irritation. Surfactant amount in solution-based formulations could be reduced. 
As well as for emulsion-based foams and solution-based foams, HPMC, MC, 
xanthan gum and their combinations were used as foam stabilizing agents. 
Formulations were preserved with sodium benzoate. Stability of BMV was 
assured through the use of phosphate buffer with pH 4.5.  
All developed compositions showed satisfactory foaming properties which 
resulted in the generation of foams of sufficient cosmetic properties and 
stability. 
A new platform propellant free vehicle for topical drug delivery was developed. 
The new developed vehicle platform offers two different formulation proposals: 
a low viscous o/w emulsion based foam and a solution based foam. Therefore, a 
propellant free foam generation mechanism was presented and evaluated. The 
later choice of the appropriate vehicle should be dependent on the application 
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site and skin condition. Abdication of propellant allows a reduction of the 
production cost and the number of production steps.   
 
4.3  Formulation development / Pressurized aerosol foams 
4.3.1  Emulsion based foams 
4.3.1.1 Formulation development steps 
The formulation development was based on a foamable formulation as 
developed for the Airspray® dispenser. The surfactants used for formulation 
development should fulfil the following functions: 
-  foam generation 
-  solubilization of BMV 
-  emulsification of oil phase 
-  emulsification of liquefied propellant 
The following formulation development steps were carried out to reach the 
product targets named above (Table 19). 
 
Table 19  Formulation development steps 
Step Target 
Reduction of surfactant fraction 
 
Reduction of skin exposure 
Reduction of water fraction 
 
Addition of a w/o surfactant 
 
Addition of polyacrylic acid 
polymers  
 
· Emulsification of liquefied propellant 
 
· Development of a homogenous emulsion
Increase of oil phase / Exchange of 
oil phase 
Dissemination improvement 
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The following components and portions thereof were used for pressurized 
aerosol foam development (Table 20). The viscosity of the formulation is not a 
limitation factor for the development of aerosol foams, as far as the formulation 
is not semisolid. All combinations were produced and evaluated due to their 
optical appearance.  
 
4.3.1.2 Evaluation of formulation stability 
After conducting the temperature stress test for all formulations, only 
formulations with a score of 7 and 8 according to the scheme after Quack et al. 
(1975), (see 3.2.2.2.2) were described as stable (Table 21).  
Formulations which became a score of 8 were described as a ’’one-phase’’ 
system; formulations which became a score of 7 were described as ’’two-phase’’ 
systems. Completely homogenous emulsions were evaluated as a ’’one-phase’’ 
system. Such formulation was produced when 8% of the propellant was added to 
the formulation shown in Table 22.  
The ’’two-phase’’ systems showed optically a strip line as the propellant phase 
was not completely emulsified in the formulation. However, it was easily 
possible to homogenize the ’’two-phase’’ systems to a homogenous emulsion 
through slightly shaking. Centrifuge test was not carried out because the 
formulations were filled into aerosol cans not applicable to a centrifuge.  All 
formulations that are listed in Table 21 showed good foamability (optical 
determination) and foam stability characteristics (light (back)-scattering 
method). Addition of Span® 80 resulted in the generation of very coarse foams 
(optical determination) which collapsed immediately. This was explained 
through the presence of oleic acid in the structure of the surfactant (see 4.1.1.2). 
Foam stability of these foams was not analytically determined.  
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Table 20 Formulation ingredients as used for the development of pressurized 
aerosol foams 
Phase     Component      Amount 
Oil phase     Miglyol® 812     1.0% - 10.0 % 
      Olive oil 
      Cyclomethicone 
      Isopropyl palmitate 
      Paraffin oil 
     Abil 100 
 
Foaming agent blend (1:1)  Tween® 20 : Brij® 35     5.0%-10.0% 
(emulsifier)         
(solubilization agent) 
    
Co-emulsifier    Lanette® O      2.0%-5.0%
      Span® 20    
      Span® 80     
      Brij® 72 
 
Emulsion stabilization agent  Pemulen® solution 0.25%  1.0%-10.0%
      Carbopol solution 0.25% 
 
Foam stabilization agent  Xanthan gum     0.05% 
 
Preservative agent   Sodium benzoate     0.1% 
 
Topical corticosteroid   BMV       0.1% 
 
Phosphate buffer pH 4.5         q. s. ad 100% 
 
 
Propellant            8.0% 
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Table 21 Stable pressurized aerosol foams 
Phase     Component      Amount 
Oil phase     Miglyol® 812     1.0% - 10.0 % 
      Olive oil      1.0% - 5.0 % 
        Cyclomethicone     1.0% - 5.0 % 
 
Foaming agent blend (1:1)  Tween® 20 : Brij® 35     4.5%-10.0% 
(emulsifier)         
(solubilization agent) 
    
Co-emulsifier    Span® 20     2.0%-5.0% 
      Brij® 72      
  
Emulsion stabilization agent  Pemulen® solution 0.25%  5.0%-10.0%
       
Foam stabilization agent  Xanthan gum     0.05% 
 
Preservative agent   Sodium benzoate     0.1% 
 
Topical corticosteroid   BMV       0.1% 
 
Phosphate buffer pH 4.5         q. s. ad 100% 
 
 
Propellant            8.0% 
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Table 22 Basic composition for pressurized aerosol foam (emulsion based) 
Phase    Component    Amount 
Oil phase    Miglyol® 812   1.0 % 
       
Foaming agent blend (1:1) Tween® 20 : Brij® 35  10.0 % 
(emulsifier)  
(solubilization agent) 
 
Foam stabilization agent Xanthan gum    0.05% 
 
Preservative agent  Sodium benzoate   0.1% 
 
Topical corticosteroid  BMV     0.1% 
 
Phosphate buffer pH 4.5      q. s. ad 100%. 
 
 
4.3.1.3 Stability of generated foams 
The stability of generated foams was evaluated as described in 3.2.1.1.3. Liquid 
drainage rate of those formulations which stability was evaluated with a score of 
7 could not be determined with the light (back-) scattering method as the drained 
liquid was not transparent enough to transmit light. Air bubble growth of 
formulations containing Miglyol® 812 and olive oil was within the range of        
-2.11 %·min-1 ± 0.25%·min-1. Formulations which contained cyclomethicone as 
oil phase showed twice as high air bubble growth, namely                    
-4.66 %·min-1 ± 0.39%·min-1. Silicone oils are known to function as foam 
inhibitors (see 2.1.3).  
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4.3.1.4 Pressurized aerosol foam vs. foam generated by Airspray® foam 
dispenser 
The stability of two foams of the same composition but generated by different 
methods determined by means of light (back-) scattering method as described in 
3.2.1.1.3 was compared to each other (Table 23). It was possible to determine 
liquid drainage rate in this case as light could be transmitted through a layer of 
drained liquid as the formulation was not opaque.  The composition of the tested 
formulation is shown in Table 22. 
 
Table 23 Stability of foams produced by two different methods 
Characteristics 
 
Airspray® dispenser 
mean ± SD 
Pressurized aerosol foam 
mean ± SD  
Bubble growth, [%·min-1] -1.82 ± 0.23 -4.80 ± 0.50 
Liquid drainage, [mm·min-1] 2.37 ± 0.30 0.44 ± 0.10 
 
The pressurized aerosol foam showed a lower foam bubble stability in 
comparison to the foam of the same composition generated with the Airspray® 
foam dispenser. Bubble growth within pressurized aerosol foam was 
approximately twice as fast as within the mechanically generated foam. The 
reason for this is an abrupt evaporation of a propellant blend at atmospheric 
pressure. The bubbles of a pressurized aerosol foam contain propellant which 
evaporates instantaneously. A pressure increase within the bubbles causes them 
to burst. In the case of mechanically generated foams, the foam bubbles contain 
air. Therefore, the bubbles of foams generated with the Airspray® dispenser a 
more stable to rupture. Nevertheless, the liquid drainage rate was approximately 
five folds higher within mechanically generated foam than within pressurized 
aerosol foam. A higher liquid drainage rates within the mechanically generated 
foams are connected with a lower gas faction of such foams than of pressurized 
aerosol foams. The same volume of a foam produced with the Airspay® 
dispenser contains percental more liquid than a pressurized aerosol foam.  
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This leads inevitably to a higher liquid drainage rate. Foam stability is, 
therefore, dependent on the foam generation mechanism. 
 
4.3.2  Solution based foams 
4.3.2.1 Formulation development steps 
Basic compositions of formulations are shown in Table 24. All combinations 
were formulated and resulted in all cases in good foamability and foam stability. 
All produced ’’two-phase’’ systems (see 4.3.1.2) passed the temperature stress 
stability test. 
 
Table 24 Basic composition of pressurized aerosol foams (solution based) 
Phase     Component      Amount 
Solvent     Propylene glycol  ≥ 11.3% 
      Hexylene glycol  ≥ 5.6% 
      Pharmasolve®  ≥ 0.8% 
      Arlasolve®   ≥ 1.9%  
       
Foaming agent    Tween® 20   3.0%  
 
Foam stabilization agent  HPMC    1.0% 
      MC    0.4% 
      HPMC / Xanthan gum 0.6% / 0.01% 
      MC / Xanthan gum 0.2% / 0.01% 
      Xanthan gum  0.03% - 0.05% 
       
 
Preservative agent   Sodium benzoate  0.1% 
 
Topical corticosteroid   BMV    0.1% 
 
Phosphate buffer pH 4.5      q. s. ad 100%  
 
 
Propellant            8.0% 
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4.3.2.2 Evaluation of formulation stability 
The stability of produced pressurized aerosol foams was detected by means of 
light (back-) scattering methods. Formulations containing HPMC at a 
concentration of 1.0% and MC at a concentration of 0.4% as foam stabilizing 
agents and different solvents for BMV in minimal possible concentrations to 
dissolve BMV were compared to each other. The results are summarized in 
Figures 55 and 56. 
No differences were found in such foam stability characteristic as foam bubble 
growth within the foams produced with different solvents. The foam bubble 
stability of foams stabilized with 1.0% HPMC and 0.4% MC was just slightly 
different. Actually, no difference between these two stabilizing agents was 
expected because of their similar surface activity.  
No transmission peaks were detected during stability determination. In the case 
of formulations where the layer of separated liquid is not opaque and can 
transmit light, absence of a transmission peak is an evidence for the absence of 
drained liquid. The absence of drained liquid is an evidence for good 
formulation stability against separation of liquid phase within a foam.   
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Figure 55 Foam bubble stability (foams with 1.0% HPMC) 
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Figure 56 Foam bubble stability (foams with 0.4% MC) 
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4.3.2.3 Pressurized aerosol foam vs. foam generated by Airspray® foam 
dispenser 
Formulations containing HPMC at a concentration of 1.0% as foam stabilizing 
agent and different solvents for BMV in minimal possible concentrations to 
dissolve BMV and generated with two different methods were compared to each 
other. The results are summarized in Table 25. 
In comparison to foams of the same composition generated with the Airspray® 
foam dispenser, pressurized aerosol foams showed lower foam bubble stability. 
Bubble growth rate by pressurized aerosol foam was more than twice as high 
compared to mechanically generated foam. Nevertheless, a liquid drainage was 
not detected at all for pressurized aerosol foams. This phenomenon was 
described before (see 4.3.1.4). It was confirmed that foam stability is dependent 
on the foam generation mechanism. 
 
Table 25 Stability of foams produced by two different methods 
Characteristics 
 
Airspray® dispenser 
mean ± SD 
Pressurized 
aerosol foam, 
mean ± SD  
Solvent 
-2.77 ± 0.20 -7.25 ± 0.19 Propylene glycol 
-2.68 ± 0.25 -7.44 ± 0.24 Hexylene glycol 
-2.72 ± 0.19 -7.50 ± 0.25  Pharmasolve® 
Bubble growth, 
[%·min-1] 
-2.73 ± 0.21 -7.41 ± 0.23 Arlasolve® 
1.56 ± 0.20 0 Propylene glycol 
1.44 ± 0.22 0 Hexylene glycol 
1.33 ± 0.21 0 Pharmasolve® 
Liquid drainage, 
[mm·min-1] 
1.55 ± 0.21 0 Arlasolve® 
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4.3.3  Summary 
Foaming formulations as pressurized aerosol foams on the base of o/w 
emulsions were successfully developed. It was possible to reduce the surfactant 
fraction so that it was still possible to solubilize BMV. It was also possible to 
increase the oil fraction in the formulations and to integrate oils of different 
viscosity and polarity such as olive oil and cyclomethicone. A co-emulsifier 
application was, nevertheless, essential. Stability of emulsions could be 
increased through addition of Pemulen® solution. Produced formulations were 
either ’’one-phase’’ or ’’two-phase’’ systems.   
It was also possible to produce pressurized aerosol foams on the basis of a 
solution of BMV using such solvents as propylene glycol, hexylene glycol, 
Pharmasolve® and Arlasolve® in different concentrations, considering the 
solubility of BMV. These systems were ’’two-phase’’ systems. 
HPMC, MC, xanthan gum and combinations thereof were used as foam 
stabilizing agents for development of both emulsion-based and solution-based 
foams. All formulations were preserved with sodium benzoate. Stability of 
BMV was assured through the use of a phosphate buffer pH 4.5.  
8% propellant was sufficient to generate foams with good optical appearance.  
It was observed that such parameters as foamability and foam stability are 
dependent on foam generation mechanism. In comparison to foams generated 
with the Airspray® dispenser, no dependency of formulation composition on 
foam quality and formulation viscosity was observed for pressurized aerosol 
foams for the tested viscosity interval.  
The developed foam vehicles present platform formulation vehicles for different 
active substances and skin conditions. This platform was developed using a 
model drug BMV. Developed foam vehicles are supposed to be used for the 
treatment of such skin conditions as psoriasis and seborrheic dermatitis of haired 
body regions. Beside corticosteroids, other therapeutical agents such as 
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antimycotics or antibiotics can be integrated into a foam vehicle. Emulsion 
based formulations as well as oil-free formulations were produced. Dependent 
on skin condition foams with different oil fractions can be used when the vehicle 
is supposed to be applied on the body region beside scalp. When the vehicle is 
supposed to be used on the scalp, oil free formulations are available. It was also 
possible to reduce the fraction of foaming agents to decrease the risk for skin 
irritation.  
 
4.4  BMV release studies 
4.4.1  Artificial membranes 
BMV release studies were carried out during 12 hours as described in 3.2.2.3. 
Commercially available Deflatop® foam and Betagalen® lotion were used as 
comparator formulations. The Deflatop® foam contains ethanol in its 
composition. The release of BMV may, therefore, be enhanced through addition 
of this excipient. Betagalen® lotion was used as an example for a BMV 
formulation in a conventional vehicle. Because of the difficulties to dose a 
uniform vehicle amount onto the membrane, it was decided to carry out the 
release studies using not a foam itself but the foamable formulation from which 
foams can be generated. Therefore, it was reasonable to include only 
formulations for the Airspray® dispenser into the study. The composition of the 
formulation used for release studies is shown in Table 22. Deflatop® foam was 
dispensed and destroyed. The liquid formulation which was left was used for the 
study. Betagalen® lotion was dosed directly as a semisolid formulation. All three 
formulations contained BMV in a concentration of 0.1%. To avoid the technical 
problem that the limited solubility of the lipophilic drug in the acceptor medium 
affects the rate of BMV release, phosphate buffer pH 4.5 containing 25% 
methanol (v/v) was used as acceptor medium. Release profiles are shown in 
Figures 57 and 58.  
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Figure 57 Release of BMV through an artificial membrane 
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Figure 58 Release of BMV through artificial membrane, saturated with isopropyl 
myristate 
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On the ordinate the cumulative BMV amount in acceptor medium is presented. 
No BMV was found in the acceptor compartment when released from 
Betagalen® lotion.  
BMV was released faster from the developed formulation than from the 
commercial Deflatop® formulation. Further on higher BMV amounts were 
released within the same time period from developed formulation compared to 
the Deflatop® formulation. After 12 hours 20.0 µg BMV (4.0% of the amount 
applied on the membrane) were found in the acceptor compartment in the case 
of Deflatop® foam and 226.9 µg BMV (45.4% of the applied amount) were 
found in the case of the developed formulation. Differences in the release 
profiles when using unsaturated artificial membranes and membranes saturated 
with isopropyl myristate were observed. Using unsaturated membranes, 
approximately an 11 fold higher amounts of BMV were released from the 
developed formulation than from Deflatop® within 12 hours (45.4% vs. 4.0% of 
the applied amount). On the other hand using membranes saturated with 
isopropyl myristate, the released BMV amount from the developed formulation 
was only 5 fold higher (17.9% vs. 3.3% of the applied amount). Using 
membranes saturated with isopropyl myristate, the overall drug release was 
found to be slower. The saturation of the membrane with a lipophilic fluid such 
as isopropyl myristate leads to an increase of the membrane lipophilicity 
reducing drug diffusion. 
These differences in the release profiles result from the differences in the 
compositions of used formulations and drug distribution in it. In Deflatop® foam 
BMV is dissolved in ethanol (99.7% v/v). In Betagalen® lotion BMV is 
dissolved in the lipophilic components of the vehicle (see Appendix). In the 
developed formulation the drug is solubilized in micelles. The size of the 
micelles is approximately 6.9 ± 0.3 nm (see 4.2.1.4.3). After the release studies 
the acceptor medium was analyzed by means of PCS measurements. In case of 
the developed formulation, micelles of the same size were found in the acceptor 
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fluid. This was an evidence that the micelles with the solubilized BMV take a 
pass through the pores of the used membranes to a higher degree than a 
dissolved BMV either in a hydrophilic or in a lipophilic vehicle. Saturation of 
the membranes with isopropyl myristate hinders the passage of the micelles 
through the pores of the membrane. Dissolution of the drug in ethanol 
(Deflatop®) hinders drug release from the vehicle. Saturation of the membrane 
with isopropyl myristate has then no effect on the drug release from the 
Deflatop® vehicle (16.5 µg vs. 20.0 µg of BMV after 12 hours). Dissolution of 
the drug in the lipophilic phase of Betagalen® lotion leads to a decrease of the 
drug release from this vehicle. In the case of this study, the released drug 
amount was below the detection limit of used analytics (HPLC).   
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4.4.2  Summary 
The use of artificial membranes was shown to be inappropriate for release 
studies when the active drug is solubilized in micelles which sizes are smaller 
than the pore size of the used membranes. The release profiles differ strongly 
from each other when using unsaturated membranes and membranes saturated 
with lipophilic fluids such as isopropyl myristate considering the release profiles 
of BMV from the developed formulation. Diffusion of surfactants through the 
artificial membrane also leads to a solubilization effect in the acceptor fluid 
which is responsible for the overall higher drug release. Saturation of the 
membrane led to a decreased amount of drug found in the acceptor compartment 
as lipophilic properties of the membrane were more pronounced and, therefore, 
the barrier properties of the St. corneum were better mimicked.  
 
4.5  BMV permeation studies 
4.5.1  Porcine ear skin 
Pig ears were taken from the slaughterhouse. Permeation studies were carried 
out as described in 3.2.2.4 over 24 hours. Two other acceptor media were used 
additionally to examine the influence of the acceptor medium composition on 
the permeation profiles of BMV. Drug permeation profiles are shown in Figures 
59, 60, 61 and 62. 
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Figure 59 Permeation of BMV through excised pig ear skin (phosphate buffer pH 4.5 
+ 25% (v/v) methanol), internal part of the ear 
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Figure 60 Permeation of BMV through excised pig ear skin (phosphate buffer pH 4.5 
+ 25% (v/v) methanol), external part of the ear 
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Figure 61 Permeation of BMV through excised pig ear skin (phosphate buffer pH 
4.5), internal part of the ear 
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Figure 62 Permeation of BMV through excised pig ear skin (phosphate buffer pH 4.5 
+ 0.1% methyl-β-cyclodextrine), internal part of the ear 
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The skin from the internal part of the pig ear was used for permeation studies. 
For the acceptor medium with ethanol the external part of the pig ear was also 
used to evaluate differences in the permeation profiles (Figure 59 and 60). 
Permeation of BMV from Deflatop® was found to be higher in all three different 
acceptor media. No differences in the BMV penetration profiles were found in 
case of the developed formulation and Betagalen® lotion. Using skin from the 
internal part of the pig ear, the following amounts of BMV were found in the 
acceptor compartment after 24 hours using phosphate buffer pH 4.5 containing 
25% (v/v) methanol: 8.9%, 4.3% and 3.6% for Deflatop®, Betagalen® and the 
developed formulation, respectively (in % of the applied amount). BMV was 
found in the acceptor medium already after 2 hours after beginning of the study 
(lag-time). When using phosphate buffer pH 4.5 alone as acceptor medium, the 
first drug amounts were found in the acceptor compartment after 10-12 hours. 
After 24 hours 6.9% (Deflatop®), 1.8% (Betagalen®) and 2.5% (developed 
formulation) of the applied drug amount were found in the acceptor medium. 
When using phosphate buffer pH 4.5 with 0.1% methyl-β-cyclodextrine, BMV 
could be detected in the acceptor medium after 6-12 hours (depending on the 
formulation). After 24 hours 14.5% (Deflatop®), 1.8% (Betagalen®) and 3.6% 
(developed formulation) were found in the acceptor medium.          
Using skin from the external part of the pig ear and phosphate buffer pH 4.5 
with 25% (v/v) methanol as acceptor medium, the following amounts of BMV 
were detected in the acceptor compartment after 24 hours: 6.2%, 2.4% and 2.7% 
for Deflatop®, Betagalen® and the developed formulation, respectively. It was 
possible to detect BMV in the acceptor medium after 2 hours after study begin. 
No particles or micelles were found in the acceptor media when they were 
analyzed by means of PCS. 
Lower amounts of permeated BMV were found when using skin from the 
external part compared to skin from the internal part of the ear. Differences in 
the permeation profiles in this case are dependent on the skin thickness.  
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BMV permeates to a greater extent through thinner skin, namely the skin from 
the internal part of the ear.  
Differences in the permeation profiles during application of three different 
acceptor media can be explained through a different solubility of BMV in these 
media. Addition of methanol and methyl-β-cyclodextrine leads to an increase of 
BMV solubility in the acceptor medium and, therefore, to a faster access of the 
drug in the acceptor compartment.     
The BMV permeation profiles obtained using pig ear skin were compared to the 
permeation profiles reported in the literature. Simonsen and Fullerton (2007) 
found between 4 and 20 µg·cm-2 BMV permeated through pig ear skin into the 
acceptor medium after 70 hours from a conventional vehicle. Degim et al. 
(1999) showed that about 2.5 µg·cm-2 BMV was permeated across canine skin 
after 48 hours. About 1-3 µg·cm-2 (Kubota and Maibach, 1993) and 8 µg·cm-2 
BMV (Kubota et al., 1992) were found in acceptor medium after 72 hours using 
human split thickness skin as a natural permeation membrane. Huang et al. 
(2005) reported 50 ng·cm-2 BMV in the acceptor compartment permeated across 
excised human skin after 24 hours from a foam vehicle. Anyway, all these data 
for BMV permeation reported much lower amounts of the drug permeated 
across different natural membranes from different vehicles.         
 
4.5.2  Biopsy and microscopy of the pig ear skin 
The histology of biopsies of pig ear skin which was used for permeation studies 
was examined to find the reason for a higher permeated BMV amount than 
reported in the literature. Biopsies were taken from the skin, fixated in 
formaldehyde solution and prepared following standard histological procedures 
(see Appendix). Sections of biopsies were investigated using microscopy 
(Figure 63). The only skin layer, which could be microscopically detected, was a 
dermis layer. An epidermis layer was not present at the border of the St. basale. 
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The dermal papillae could still be detected. It was obvious that the epidermis 
layer with the St. corneum was somehow removed between the time of slaughter 
and picking up the skin from the slaughterhouse. After literature analysis no 
special references were found considering the skin preparation and the exact 
time of the ears displacement from the rest of the carcass of the slaughtered 
animal.   
 
 
Figure 63 Histology of porcine skin as used for permeation studies 
 
Such descriptions as ’’pig ears were obtained no more than a few hours post-
mortem’’, ’’pig ears were obtained from a local abbatoir’’, ’’ears were obtained 
from pigs slaughtered on the day of the experiment’’ or no detailed instructions 
at all were found in the literature (Dick and Scott, 1992; Meyer, W., 1996; 
Sekkat et al., 2002; Jacobi et al., 2007). Even in the test guidelines for in vitro 
assessment of dermal absorption and percutaneous penetration of cosmetic 
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ingredients (Diembeck et al., 1999), no detailed descriptions were given for the 
process of skin displacement in the slaughterhouse.  
The carcasses of the slaughtered animals are exposed to the high-temperature 
cleaning procedure prior to further processing. This cleaning procedure causes a 
displacement of the upper skin layer up to the basal cells, which makes the skin 
inappropriate for the use for permeation studies as the main permeation barrier, 
namely the St. corneum, is destroyed. The ears of the animals should, therefore, 
be displaced from the carcass directly after slaughter and before high-
temperature cleaning. More detailed instructions for a skin obtaining procedure 
should be given in the literature and the guidelines for performing the 
permeation studies.  
 
4 Results and Discussions 
 154
4.5.3  Full thickness pig ear skin 
It was assured that the animals were not scaled with hot water before the ears 
were separated. Otherwise, the epidermis would be completely removed. The 
skin was histologically investigated. The St. corneum consisted of compactly 
organized keratinocytes (Fig. 64). The most prominent layer of the viable 
epidermis beneath was the St. granulosum also containing keratinocytes. At the 
border to the dermis, basal cells were determined. The dermal papillae were 
numerous and prominent in the epidermis.  
 
 
Figure 64 Histology of porcine full thickness skin 
 
The permeation studies were performed again using the phosphate buffer pH 4.5 
containing 25% methanol (v/v) as acceptor medium and the internal part of the 
pig ear skin. Following permeation profiles were obtained (Figure 65). 
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Figure 65 Permeation of BMV through full thickness porcine skin (acceptor 
medium: phosphate buffer pH 4.5 + 25% (v/v) methanol), internal part of 
the ear 
 
The highest BMV amount was found after 24 hours in the acceptor medium 
when Deflatop® was applied into the donor compartment (4.4 µg, which makes 
out a 0.9% of the applied amount). No difference in the permeation profiles of 
BMV across the membrane was found, when the developed formulation and 
Belagalen® lotion were used (0.5 µg and 0.3 µg, respectively). Permeation of 
BMV took place after an 8-hours lag-time using Deflatop® and after 12-hours 
lag-time using the developed formulation and Betagalen®. No particles were 
found in the acceptor media when they were analyzed by means of PCS. The 
amount of BMV found in the acceptor compartment actually reflects the drug 
amount which reaches the systemic circulation. In case of topically used 
corticosteroids, the systemic drug absorption should be avoided to exclude a risk 
of side effects development. Permeation of BMV across the skin from the 
developed formulation and Betagalen® lotion took place to a minor degree. 
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4.5.4  Summary 
It could be shown by means of performed permeation studies using porcine skin 
as a model for human skin that the permeation of BMV and, therefore, the risk 
of systemic absorption is lower when using one of the developed formulations 
with high surfactant fraction or Betagalen® lotion than the marketed Deflatop® 
foam. The increased permeation rate of BMV from Deflatop® can be explained 
through the presence of ethanol in the composition which acts as a typical 
permeation enhancer. Ethanol is known to increase the flux of the lipophilic 
drugs across the skin by extracting the St. corneum lipids (Williams et al., 
1992).   
The relatively high surfactant fraction in the developed formulation does not 
seam to influence the drug permeation rate to a greater extent than ethanol does, 
although, surfactants are also used as skin-permeation enhancers in the galenical 
formulation development. Anionic surfactants, e.g. sodium lauryl sulfate, are 
shown to cause swelling of the St. corneum and interact with keratin. Nonionic 
surfactants which were used for formulation development are reported to act as 
weaker permeation enhancers (Ritschel and Hussain, 1988; Williams et al., 
1992).   
It was also shown that a detailed description of the skin preparation procedure is 
necessary to be given at least in such regulatory papers as guidelines to avoid a 
faulty comparative data interpretation of the permeation studies. 
     
 
 
5 Overall summary 
 157
5 Overall summary 
As a first achievement of this work, a new comprehensive approach for routine 
characterization of foams as drug vehicles in the formulation development stage 
was developed. This approach was proposed as an alternative to the methods of 
Eur. Ph. 6.0 and is extended to the determination of foam stability - a parameter 
which is not considered in the monograph. A simple cylinder test is proposed to 
be used for the determination of foamability. Firmness and cohesiveness of the 
produced foams can be determined using texture analysis. Foam stability as a 
function of liquid drainage can be brought in connection to the transmission 
intensity detected with the light (back-) scattering method or determined through 
calculation of foam liquid stability using the cylinder method. Foam stability as 
a function of bubble rupture can be described with the foam volume stability 
parameter utilizing the same method. Observation of backscattering intensities 
with the light (back-) scattering method helps to evaluate foam bubble size 
growth caused by the Ostwald ripening within foams. A fast and extensive 
screening of potential formulations during galenical development or quality 
control is possible when this developed set of analytical tests is combined.  
Two new formulation platforms were developed during this work: propellant-
free foams and pressurized aerosol foams as vehicles for topical drug delivery. 
These developed foam vehicles present platform formulation vehicles for 
different active substances and skin conditions. The platform was developed 
using the model drug betamethasone-17-valerate. The developed vehicles are 
supposed to be used for the treatment of such skin conditions as psoriasis and 
seborrheic dermatitis of haired body regions. Besides corticosteroids, other 
therapeutical agents such as antimycotics or antibiotics can be also integrated 
into these foam vehicles. 
Two formulation approaches were employed within the both platforms: 
development of foams based on low viscous o/w emulsion and solution-based 
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foams. The appropriate vehicle can then be chosen dependent on the application 
site and skin condition such as skin moisture content and degree of hair-growth.    
Nano-emulsions with a low oil phase fraction were developed using the high-
energy emulsification method for their production. Sufficient formulation 
stability during storage as well as delivery of the equivalent active ingredient 
dose when applied was assured. 
In the developed solution-based foamable formulations, betamethasone-17-
valerate was dissolved in such solvents as propylene glycol, hexylene glycol, N-
methyl-2-pyrrolidone and dimethyl isosorbide.   
All developed compositions showed satisfactory foaming properties which 
resulted in the generation of foams of sufficient cosmetic properties and 
stability. 
During the studies, the Airspray® dispenser was approved as a device for the 
generation of propellant-free pharmaceutical foams. The dispenser was able to 
deliver uniform doses of the corticosteroid in the generated foam. An upper 
viscosity limit was also established for the Airspray® dispenser – a maximal 
viscosity value up from which the foam generation with the Airspray® dispenser 
is not possible. This limit was determined to be 30 mPa·s.  
During pre-formulation studies it was shown that foamability and foam stability 
of the developed formulations could be improved through the addition of such 
polymers as hydroxypropyl methyl cellulose, methyl cellulose, xanthan gum and 
their combinations. 
By the means of permeation studies across porcine ear skin it could be shown 
that the systemic absorption of BMV is lower using one of the developed 
formulations than the systemic absorption of BMV from the commercially 
available Deflatop® foam and similar to the systemic absorption of BMV from 
Betagalen® lotion. 
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6 Summary (German version)   
Einer der Gegenstände der vorliegenden Arbeit war die Entwicklung eines 
neuen umfassenden Verfahrens zur routinemäßigen Charakterisierung von 
Schäumen als therapeutische Vehikel während der Phase der 
Formulierungsentwicklung. Dieses Verfahren sollte als eine Alternative zu dem 
im Arzneibuch (6.0) beschriebenen Verfahren dienen und um die Bestimmung 
der Schaumstabilität erweitert sein. Die Bestimmung der Schaumstabilität ist im 
Arzneibuch nicht vorgesehen. Die Zylindermethode war zur Bestimmung der 
Aufschäumbarkeit einer Formulierung vorgesehen. Die Festigkeit und die 
Kohäsion eines Schaums konnten mit dem Texture Analyser bestimmt werden. 
Die Stabilität des Schaums als Funktion der Flüssigkeitsdrainage konnte mit der 
Transmissionsintensität eines Lichtstrahles in Verbindung gebracht werden oder 
durch die Bestimmung des FLS-Parameters (Foam Liquid Stability) während 
der Zylindermethode erfasst werden. Die Transmissionsintensität wurde mit 
dem Licht (Rück)Streuungs-Verfahren gemessen. Die Stabilität eines Schaums 
als Funktion der Stabilität der Schaumblasen konnte durch die Berechnung des 
FVS-Parameters (Foam Volume Stability) bestimmt werden. Durch die 
Beobachtung der Rückstreuintensitäten des Lichtes mit dem Licht 
(Rück)Streuungs-Verfahren konnte die Zunahme der Größe der Schaumblasen 
als das Resultat der Ostwaldreifung in einem Schaum erfasst werden. Durch die 
Kombination dieser Methoden ist eine schnelle und umfangreiche Selektion der 
potentiellen Formulierungen während der galenischen Entwicklung oder 
während einer Qualitätskontrolle möglich.             
Zwei neue Formulierungsplattformen zur Therapie topischer Krankheiten 
konnten auch entwickelt werden: der treibgasfreie Schaum und der Schaum in 
einer Aerosoldruckgaspackung. Diese neuen Formulierungsplattformen stellen 
neue Grundlagen für verschiedene Arzneistoffe und Hautzustände dar. Diese 
Formulierungen wurden unter der Anwendung des Modellarzneistoffes, 
Betamethasonvalerat entwickelt. Die neuen entwickelten Formulierungen 
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können zur Therapie solcher Hautkrankheiten wie Psoriasis und seborrhoische 
Dermatitis auf behaarten Körperarealen angewendet werden. Außer 
Kortikosteroiden können auch Arzneistoffe aus anderen therapeutischen 
Gruppen, wie zum Beispiel Antimykotika oder Antibiotika, in diese 
Schaumvehikel eingearbeitet werden. 
Zwei Formulierungsansätze wurden für beide Plattformen eingesetzt: Die 
Entwicklung eines Schaums auf der Basis einer niedrig-viskosen O/W-Emulsion 
und Entwicklung eines lösungsbasierten Schaums. Das entsprechend geeignete 
Vehikel kann dann in Abhängigkeit von dem Applikationsort und dem 
Hautzustand, wie zum Beispiel Hauthydratationszustand und Behaarungsdichte, 
gewählt werden.    
Nanoemulsionen mit einem niedrigen Gehalt einer Ölphase wurden mit dem 
Verfahren der Hochenergieemulgierung entwickelt und hergestellt. Sowohl eine 
ausreichende Stabilität der Formulierungen während der Lagerung als auch die 
Abgabe einer equivalenten Dosis des Wirkstoffes wurde gewährleistet.  
Bei der Herstellung von lösungsbasierten Schäumen wurden Lösungsmittel wie 
Propylenglykol, Hexylenglykol, N-Methyl-2-Pyrrolidon und Methylisosorbid 
verwendet. Die entwickelten Formulierungen waren sowohl durch eine 
zufrieden stellende Aufschäumbarkeit als auch eine ausreichende 
Schaumstabilität und ausgezeichnete kosmetische Eigenschaften 
gekennzeichnet.  
Es konnte gezeigt werden, dass der Airspray® Schaumspender zur Herstellung 
pharmazeutischer treibgasfreier Schäume gut geeignet ist. Der Schaumspender 
ist in der Lage, eine uniforme Dosis des Kortikosteroids abzugeben. Die obere 
Viskositätsgrenze wurde für den oben genannten Schaumspender festgestellt; sie 
betrug 30 mPa·s. Oberhalb dieser Grenze ist keine Schaumproduktion möglich.  
Während der Formulierungsentwicklung wurde gezeigt, dass die Zugabe von 
Polymeren wie Hydroxypropylmethylcellulose, Methylcellulose, Xanthan und 
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deren Kombinationen zu den Rezepturen eine Verbesserung der 
Aufschäumbarkeit und der Schaumstabilität hervorrufen kann. 
Anhand der durchgeführten Permeationsstudien durch Schweinehaut wurde 
gezeigt, dass die systemische Absorption des Modellwirkstoffes aus einer der 
entwickelten Formulierung geringer als die systemische Absorption des 
Modellwirkstoffes aus Deflatop® Schaum und vergleichbar zur systemischen 
Absorption des Modellwirkstoffes aus Betagalen® Lotion ist.              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 Appendix 
 162
7 Appendix 
 
HPLC analysis 
Betamethsone-17-valerate was assayed by HPLC on a reverse phase column 
with external calibration and UV detection (Kontron, Kontron Instruments, 
Italy). The measurements were carried out under isocratic conditions. The 
mobile phase consisted of solvents in HPLC-quality and double distilled water 
from a Finn Aqua 75-E-4 distillery (FinnAqua, Finland). The mobile phase was 
degassed at ambient temperature.  
 
Precolumn:   LiCroChart 4-4 
    Merck KGaA, Germany 
Column:   LiCroChart 125-4; 12.5 cm 
    Merck KGaA, Germany 
Stationary phase:  LiCrospher 100 RP-18 (5 µm) 
Mobile phase:  Acetonitrile  450 ml 
    Water   550 ml 
Wavelength:  254 nm 
Flow rate:   1.2 mL/min 
Injected volume:  80 µl 
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Skin biopsy and microscopy 
Skin biopsies were taken from the both sides of pig ear. They were fixed in 
formaldehyde solution (Alfa Aesar GmbH & Co., Germany), dehydrated 
(Tissue-TekR VIP, Sakura, Germany), treated with ethanol 50%, 60%, 70%, 96% 
(v/v, C. Roth GmbH CoKG, Germany), isopropanol (C. Roth GmbH CoKG, 
Germany), xylol (Alfa Aesar GmbH & Co., Germany) and subsequently 
embedded in paraffin (MKR & Co. Ltd, UK). Sections of approx. 4 µm 
thickness were cut vertically to the surface using a microtome (Jung AG, 
Germany). The paraffin layer was removed through tempering the samples in a 
heated cabinet for 40 min at 68°C. The sections were immersed subsequently in 
xylol, ethanol 96% (v/v), ethanol 70% (v/v) and distilled water dips. Afterwards, 
the sections were stained with haematoxyline (Gill III, Shandon, Germany) / 
eosine (Abbey Color, USA) following standard histological procedures. Images 
were taken using a digital microscope (VHX-500, Keyence, Japan). 
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Foamability method, modified after Jellinek (1959) / Foaming agents 
Trade name Group C, % Scale_11 
 
Scale_22 Scale_33 
Medialan® 
 
Anionic 1 
2 
3 
4 
5 
4.5 
4.0 
4.5 
5.0 
2.0 
4.0 
3.0 
4.0 
4.5 
2.0 
3.0 
2.0 
2.0 
4.0 
1.5 
Hostapon® 
 
Anionic 1 
2 
3 
4 
5 
4.5 
4.0 
4.5 
5.0 
3.5 
4.3 
4.0 
4.3 
4.8 
3.0 
4.0 
4.0 
4.2 
4.5 
1.2 
Serwet® WH 172 
 
Anionic 1 
2 
3 
4 
5 
6.5 
5.8 
5.0 
6.0 
5.5 
6.0 
5.0 
5.0 
5.5 
5.2 
6.0 
4.8 
5.0 
5.5 
5.0 
Rewopol® SB CS 50K 
 
Anionic 1 
2 
3 
4 
5 
4.5 
4.2 
4.5 
4.3 
4.0 
4.2 
4.0 
4.2 
4.0 
3.8 
4.0 
4.0 
4.0 
4.0 
3.5 
Texapon® K 12 
 
Anionic 1 
2 
3 
4 
5 
7.0 
7.0 
7.0 
7.0 
7.0 
5.0 
6.0 
6.0 
6.0 
6.0 
5.0 
5.0 
6.0 
6.0 
6.0 
TEGO Betain® L7  
 
Amphoteric 1 
2 
3 
4 
5 
4.8 
5.1 
5.5 
5.2 
5.3 
4.5 
5.0 
5.5 
5.0 
5.2 
4.5 
5.0 
5.5 
5.0 
5.1 
TEGO Betain® 810 
 
Amphoteric 1 
2 
3 
4 
5 
3.0 
2.0 
4.2 
4.0 
4.2 
1.5 
1.8 
1.2 
3.8 
3.8 
1.2 
1.7 
0 
3.5 
3.2 
TEGO Care® CG90 
 
Nonionic 1 
2 
3 
4 
5 
2.0 
1.5 
1.5 
- 
- 
2.0 
1.5 
1.5 
- 
- 
2.0 
1.5 
1.5 
- 
- 
Plantaren® 818 UP 
 
Nonionic 1 
2 
3 
4 
5 
5.0 
5.5 
6.0 
5.5 
6.0 
4.5 
5.3 
5.8 
5.2 
5.5 
4.5 
5.0 
5.8 
5.0 
5.5 
Sucrose laurate 
 
Nonionic 1 
2 
3 
4 
5 
2.0 
2.2 
2.0 
2.5 
3.5 
2.0 
2.2 
2.0 
2.3 
3.0 
1.8 
2.0 
1.8 
2.2 
2.8 
Imwitor® 380 
 
Nonionic 1 
2 
3 
4 
5 
1.3 
1.3 
1.5 
1.5 
1.5 
1.2 
1.2 
1.3 
1.3 
1.3 
1.2 
1.2 
1.2 
1.3 
1.2 
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Trade name Group C, % Scale_11 
 
Scale_22 Scale_33 
ABIL® Care 85 
 
Nonionic 1 
2 
3 
4 
5 
1.4 
1.4 
1.1 
1.1 
1.1 
1.0 
1.0 
1.1 
1.1 
1.1 
0 
0 
0 
0 
0 
Teginacid®C 
 
Nonionic 1 
2 
3 
4 
5 
2.1 
2.3 
2.5 
2.5 
2.8 
1.8 
2.1 
2.2 
2.2 
2.3 
1.5 
2.0 
2.1 
2.0 
2.1 
Eumulgin®B2 
 
Nonionic 1 
2 
3 
4 
5 
2.0 
1.3 
3.8 
2.5 
2.0 
1.8 
1.2 
2.0 
1.5 
1.5 
1.5 
1.1 
1.5 
1.2 
1.3 
TAGAT® CH 40 
 
Nonionic 1 
2 
3 
4 
5 
1.5 
1.5 
1.8 
1.8 
1.8 
1.2 
1.2 
1.3 
1.5 
1.5 
1.1 
1.2 
1.2 
1.3 
1.3 
TAGAT® S2 
 
Nonionic 1 
2 
3 
4 
5 
1.2 
1.2 
1.5 
1.5 
1.5 
1.2 
1.2 
1.3 
1.3 
1.4 
1.2 
1.2 
1.2 
1.2 
1.2 
TAGAT® 02 
 
Nonionic 1 
2 
3 
4 
5 
2.1 
2.1 
2.1 
2.5 
2.3 
2.0 
2.1 
2.0 
2.3 
2.0 
1.9 
2.0 
1.8 
2.0 
2.0 
TAGAT® L2 
 
Nonionic 1 
2 
3 
4 
5 
3.0 
2.5 
3.0 
3.0 
2.3 
2.8 
2.2 
2.5 
2.5 
2.0 
2.5 
2.0 
2.2 
2.2 
1.8 
TEGO® SML 
 
Nonionic 1 
2 
3 
4 
5 
1.2 
1.2 
1.2 
1.2 
1.5 
1.2 
1.1 
1.1 
1.1 
1.3 
1.2 
1.1 
1.1 
1.1 
1.2 
Brij® 35 
 
Nonionic 1 
2 
3 
4 
5 
6.0 
7.0 
5.5 
6.0 
5.0 
4.0 
2.0 
2.0 
2.0 
2.0 
4.0 
1.3 
1.3 
1.4 
1.5 
Brij® 58 
 
Nonionic 1 
2 
3 
4 
5 
2.0 
2.0 
2.3 
3.0 
2.0 
2.0 
1.8 
1.8 
3.0 
1.5 
1.8 
1.6 
1.5 
3.0 
1.5 
Brij® 98 
 
Nonionic 1 
2 
3 
4 
5 
4.0 
2.0 
5.0 
4.0 
4.0 
3.2 
2.0 
4.0 
3.5 
4.0 
3.0 
2.0 
3.5 
3.5 
4.0 
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Trade name Group C, % Scale_11 
 
Scale_22 Scale_33 
Tween® 20 
 
Nonionic 1 
2 
3 
4 
5 
3.0 
4.0 
4.2 
4.0 
4.0 
2.5 
3.8 
4.0 
4.0 
3.8 
2.2 
3.8 
3.8 
3.6 
3.8 
Tween® 40 
 
Nonionic 1 
2 
3 
4 
5 
1.5 
1.5 
2.0 
1.5 
1.5 
1.3 
1.3 
1.8 
1.5 
1.5 
1.3 
1.3 
1.5 
1.3 
1.3 
Tween® 60 
 
Nonionic 1 
2 
3 
4 
5 
1.5 
1.8 
1.5 
1.4 
1.5 
1.5 
1.5 
1.3 
1.4 
1.3 
1.4 
1.4 
1.3 
1.2 
1.2 
Tween® 80 
 
Nonionic 1 
2 
3 
4 
5 
1.8 
2.0 
3.0 
1.8 
2.0 
1.8 
1.8 
3.0 
1.5 
1.8 
1.6 
1.8 
3.0 
1.5 
1.6 
 
1 – direct after foam production 
2 – after 15 min 
3  – after 30 min 
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Composition of Deflatop® foam 
0.1% Betamethasone-17-valerate  
Hexadecan-1-ol 
Stearyl alcohol 
Poylsorbat 60 
Ethanol 99.7% 
Purified water 
Propylene glycol 
Citric acid 
Potassium citrate 
Pressurized with a hydrocarbon (butane/propane/2-methylpropene) propellant 
 
Composition of Betagalen® lotion 
0.1% Betamethasone-17-valerate  
Phenoxy ethanol 
Decyl oleate 
Cetyl stearyl alcohol 
Cetomacrogol 1000 
Propylene glycol 
Dimeticon 20 
Citric acid  
Sodium monohydrogene phosphate  
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Equipment 
Analytical balance  Sartorius A200S, Sartorius AG, Germany 
Autosampler / HPLC Kontron Autosampler 565, Kontron Instruments, Italy 
Detector / HPLC Kontron HPLC-Detector 540, Kontron Instruments, 
Italy 
Microanalytical balance Sartorius 4501 micro, Sartorius AG, Germany 
pH-meter                pH 540 GLP, WTW GmbH & Co. KG, Germany 
Pump / HPLC   Kontron, Kontron Instruments, Italy 
Software / HPLC  Kontron Data System, Kontron Instruments, Italy 
Thermometer     VOLTCRAFT® Data-Logger Thermometer 306 
    Voltcraft AG, Germany 
Thermostat bath  HAAKE K, HAAKE, Germany 
Thermostatic unit  Rumed 3501, Rubarth Apparate GmbH, Germany 
Timer    Hanhart, Hanhart, Germany 
Ultrasound bath Bandelin Sonorex Super RK 106, Bandelin electronic, 
Germany 
Ultra-turrax   T25 basic IKA Labortechnik, Germany 
Volumetric pipette  Eppendorf AG, Germany 
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Chemicals 
Acetonitrile   C. Roth GmbH CoKG, Germany 
Kalium dihydrogen  Merck KG, Germany 
phosphate monohydrate  
Methanol   C. Roth GmbH & CoKG, Germany 
Methyl-β-cyclodextrine Chemos GmbH, Germany 
Sodium benzoate  Riedel-de Haen AG, Germany 
Sodium dihydrogen  Merck KG, Germany 
phosphate 
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